

New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR

Kenneth Maiese¹

¹*Cellular and Molecular Signaling, New York, New York 10022*

TABLE OF CONTENTS

1. Abstract
2. Introduction: The global impact of metabolic disease and diabetes mellitus
 - 2.1. Non-communicable diseases
 - 2.2. Metabolic disease and diabetes mellitus
3. Novel avenues to target metabolic Disease and diabetes mellitus
4. The vitamin nicotinamide
 - 4.1. Production and metabolism of nicotinamide
 - 4.2. Nicotinamide, normal physiology, and disease states
5. Nicotinamide and metabolic dysfunction
 - 5.1. Nicotinamide and diabetes mellitus
 - 5.2. Nicotinamide and maintenance of mitochondrial function
6. Nicotinamide, pathways of cell death, and autophagy
 - 6.1. Apoptotic cell death
 - 6.2. Autophagy
7. Nicotinamide and the mechanistic target of rapamycin
 - 7.1. Nicotinamide and mTOR
 - 7.2. mTOR as a component of mTORC1
 - 7.3. mTOR as a component of mTORC2
 - 7.4. mTOR and AMP activated protein kinase
8. Nicotinamide, mTOR, AMPK, and metabolic disorders
 - 8.1. mTOR and metabolic function
 - 8.2. Nicotinamide and the downstream pathways of mTOR
 - 8.3. Nicotinamide and the necessary modulation of autophagy with mTOR
9. Future Perspectives for nicotinamide
10. Acknowledgments
11. References

1. ABSTRACT

Metabolic disorders, such as diabetes mellitus (DM), are increasingly becoming significant risk factors for the health of the global population and consume substantial portions of the gross domestic product of all nations. Although conventional therapies that include early diagnosis, nutritional modification of diet, and pharmacological treatments may limit disease progression, tight serum glucose control

cannot prevent the onset of future disease complications. With these concerns, novel strategies for the treatment of metabolic disorders that involve the vitamin nicotinamide, the mechanistic target of rapamycin (mTOR), mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP activated protein kinase (AMPK), and the cellular pathways of autophagy and apoptosis offer exceptional promise to

Table 1. Highlights of metabolic oversight by nicotinamide through autophagy and mTOR

1. As important NCDs, metabolic disorders and DM are increasingly being recognized as critical targets to develop novel treatment strategies to limit death and disability for the world's population. 2. Although conventional therapies that include early diagnosis, nutritional modification of diet, and pharmacological treatments may slow disease progression, they cannot prevent the onset of future disease complications with metabolic disorders. 3. The vitamin nicotinamide, mTOR, mTORC1, mTORC2, AMPK, and the cellular pathways of autophagy and apoptosis offer innovative strategies to provide new treatment options for metabolic disorders. 4. Nicotinamide and the oversight of mTOR pathways that are associated with growth factors, such as EPO, and inhibitors of nicotinamide, such as SIRT1, can foster cellular energy homeostasis, improve glucose utilization, and preserve pancreatic b-cell function. 5. However, in order to optimize translation to positive clinical outcomes, a fine modulatory control is required for nicotinamide, AMPK, and autophagy pathways during metabolic disorders. Control of these complex pathways must account for parameters such as cellular levels of NAD⁺ generated by nicotinamide that can, under some scenarios, lead to reduced pancreatic b-cell function, insulin resistance, mitochondrial oxidative stress, and cell death. 6. With these observations, it is evident that targeting nicotinamide as an effective agent to treat metabolic disorders requires careful scrutiny of the fine balance in activity required for mTOR and autophagic pathways.
AMPK: AMP activated protein kinase; DM: diabetes mellitus; EPO: erythropoietin; mTOR: mechanistic target of rapamycin; mTORC1: mTOR Complex 1; mTORC2: mTOR Complex 2; NCD: non-communicable disease; SIRT1: silent mating type information regulation 2 homolog 1 (<i>S. cerevisiae</i>)

provide new avenues of treatment. Oversight of these pathways can promote cellular energy homeostasis, maintain mitochondrial function, improve glucose utilization, and preserve pancreatic β -cell function. Yet, the interplay among mTOR, AMPK, and autophagy pathways can be complex and affect desired clinical outcomes, necessitating further investigations to provide efficacious treatment strategies for metabolic dysfunction and DM.

2. INTRODUCTION: THE GLOBAL IMPACT OF METABOLIC DISEASE AND DIABETES MELLITUS

2.1. Non-communicable diseases

Metabolic disorders, such as diabetes mellitus (DM), form a significant component of non-communicable diseases (NCDs). Of concern, NCDs are increasing in incidence throughout the world. According to the World Health Organization, approximately seventy percent of deaths that are recorded each year are the result of NCDs (1, 2). Wealthy as well as low income countries are affected. More than ten percent of the population less than sixty years of age is affected in high-income countries (1). Interestingly, of the over forty million people that die each year from NCDs, fifteen million individuals are younger with ages between thirty and sixty-nine years old. Yet, NCDs affect a greater proportion of the population in low and middle-income countries

with at least one-third of the population under the age of sixty suffering from NCDs.

This rise in NCDs parallels the observed increase in life expectancy of the world's population (3). The age of the world's population continues to increase with new estimates of life expectancy approaching eighty years of age (4). With life expectancy marked by a one percent decrease in the age-adjusted death rate from the years 2000 through 2011 (5), the number of individuals over the age of sixty-five has been noted to double during the previous 50 years (6). Furthermore, the number of older individuals in large developing countries such as India and China also will increase from five to ten percent over the next several decades (7, 8). Multiple factors may account for the observed increased in lifespan for the world's population. These include improvements in treatments for multiple disorders that involve endocrine disease, vascular disease, acute neurodegenerative disorders, and nutrition as well as improved access to preventive care (9-13).

2.2. Metabolic disease and diabetes mellitus

As an important NCD, DM is increasingly being recognized as a target to develop novel treatment strategies to reduce death and disability for the world's population (14-16) (Table 1). Approximately eighty percent of adults with DM are living in low- and middle-income countries (17). More

than \$20,000 USD are required to care for each individual with DM per year. The care for patients with DM equals approximately \$760 billion United States Dollars (USD) (17) and consumes more than seventeen percent of the Gross Domestic Product in the United States (US) as reported by the Centers for Medicare and Medicaid Services (CMS) (18). With the loss of function and disability that results from DM, an estimated sixty-nine billion USDs are consumed from reduced productivity linked to DM.

To add to these financial concerns for DM, the number of individuals with DM is expected to rise to seven hundred million individuals by the year 2045 according to the International Diabetes Federation (17). Currently, it is believed that close to five hundred million individuals have DM (7, 19-22). An additional four hundred million individuals also have some form of metabolic disease and are at risk for developing DM but remain undiagnosed at this time (17, 23-25).

Obesity in the general population is considered to be another risk factor for the development of DM. Obesity results in impaired glucose tolerance that leads to DM progression (26-28). As a result, impaired glucose tolerance and obesity increases the risk of developing DM in young individuals (29). Obesity with excess body fat also can affect stem cell proliferation, aging, inflammation, oxidative stress injury, and mitochondrial function (28, 30-35).

DM affects all systems of the body. For example, in the peripheral nervous system, at least seventy percent of individuals with DM can develop some degree of diabetic peripheral neuropathy. DM can lead to both autonomic neuropathy (36) and peripheral nerve disease (37, 38). Assessments of peripheral neuropathies can be challenging, since the disorder is chronic in nature, may be sub-clinical, and prior deficits may go undetected even after improved control over glucose homeostasis has been initiated. In the central nervous system, DM can cause insulin resistance and dementia in patients with Alzheimer's disease (AD) (16, 39, 40). DM can affect multiple cellular pathways that lead to the progression of cognitive loss (7, 41-45). DM also has been linked to mental illness (46, 47), cerebral

vascular injury (7, 24, 48-51), impairment of microglial activity (16, 39, 40), and can impact stem cell proliferation (7, 41-45). In addition, DM can result in endothelial dysfunction (3, 7, 52-54), cardiovascular disease (25, 26, 53, 55-61), retinal disease (62-64), and immune function disorders (65-70).

3. NOVEL AVENUES TO TARGET METABOLIC DISEASE AND DIABETES MELLITUS

Given the significant death and disability that metabolic disease and DM can cause in the global population with a severe financial drain on world economies, it is clear that new avenues of therapeutic discovery are required. With conventional therapies, early diagnosis of DM and rapid treatment can offer some degree of protection and may inhibit the progression of DM (3, 21, 71-75). Yet, tight serum glucose control does not always resolve the complications from DM (29, 76). In addition, use of diet control treatments may be effective to prevent hyperglycemic events, but these strategies have potential risks that can decrease organ mass through processes that involve autophagy (77). As a result, new avenues for therapeutic strategies to address metabolic disorders are urgently needed. One novel strategy that offers exciting prospects involves the agent nicotinamide and the pathways associated with the mechanistic target of rapamycin (mTOR), mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP activated protein kinase (AMPK), and programmed cell death with autophagy and apoptosis (Table 1).

4. THE VITAMIN NICOTINAMIDE

4.1. Production and metabolism of nicotinamide

The vitamin nicotinamide is the amide form of vitamin B₃ (niacin). It is obtained through synthesis in the body or as a dietary source and supplement, such as from animal sources or plants (78). Nicotinic acid is the other form of the water-soluble vitamin B₃ (79). The principal form of niacin in dietary plant




Figure 1. Nicotinamide and metabolic disease. Nicotinamide is generated through the conversion of nicotinic acid in the liver as one source. Once nicotinamide is obtained in the body, it serves as the precursor for NAD⁺. Nicotinamide through the mechanistic target of rapamycin (mTOR), mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), AMP activated protein kinase (AMPK), and pathways of autophagy and apoptosis offer innovative strategies to treat metabolic disorders such as diabetes mellitus (DM). For example, during DM, AMP activated protein kinase (AMPK) can limit mitochondrial stress, mTOR Complex 1 (mTORC1), can increase pancreatic β-cell mass, mTOR Complex 2 (mTORC2) can improve insulin resistance, autophagy can foster glucose homeostasis, and blockade of apoptosis can prevent cellular membrane phosphatidylserine (PS) externalization to promote cell longevity. Further appreciation and understanding of the complexities of these pathways can foster new strategies for translation into innovative treatments for metabolic disorders, such as DM.

sources is nicotinic acid that is rapidly absorbed through the gastrointestinal epithelium (80). Nicotinamide is generated through the conversion of nicotinic acid in the liver or through the hydrolysis of the coenzyme β-nicotinamide adenine dinucleotide (NAD⁺) (Figure 1). Once nicotinamide is obtained in the body, it serves as the precursor for NAD⁺ (81, 82). It is also necessary for the synthesis of nicotinamide adenine dinucleotide phosphate (NADP⁺) (83). Initially, nicotinamide is changed to its mononucleotide form (NMN) with the enzyme nicotinic acid/nicotinamide adenylyltransferase yielding the dinucleotides NAAD⁺ and NAD⁺. NAAD⁺ converts to NAD⁺ through NAD⁺ synthase (84) or NAD⁺ can be synthesized through nicotinamide riboside kinase that phosphorylates nicotinamide riboside to NMN (85, 86).

4.2. Nicotinamide, normal physiology, and disease states

Nicotinamide through NAD⁺ has a critical physiological role in cellular metabolism and can be

directly utilized by cells to synthesize NAD⁺ (82, 87, 88). Nicotinamide also participates in energy metabolism through the tricarboxylic acid cycle by utilizing NAD⁺ in the mitochondrial respiratory electron transport chain for the production of ATP, DNA synthesis, and DNA repair (89-91). Under some circumstances, nicotinamide can preserve mitochondrial function as a mechanism to enhance cellular survival (82, 92). Some studies suggest that the specific levels of NAD⁺ can be the critical factor for cell survival (88, 93, 94). Increased administration of nicotinamide may be useful against tumorigenesis (95) and lead to apoptotic cell death in cancer cells (96, 97).

If nicotinamide is depleted in the body, fatigue, loss of appetite, pigmented rashes of the skin, and oral ulcerations can result. More severe states of deficiency lead to pellagra that is characterized by cutaneous rashes, oral ulcerations, gastrointestinal difficulties, and cognitive loss (98). Pellagra can occur during conditions of low nicotinamide or the inability to absorb nicotinamide

(99). As a result, the cellular pathways of nicotinamide are essential for energy metabolism and are directly tied to normal physiological processes as well as disease states that include inflammatory pathways (100), energy metabolism (72), vascular disease (101, 102), alcohol toxicity (103), and oxidative stress (88, 104, 105).

During periods of cellular injury that can involve oxidative stress (21, 106), reactive oxygen species can be scavenged by endogenous antioxidant systems that include nicotinamide, superoxide dismutase, glutathione peroxidase, catalase, and small molecule substances such as vitamins C, D, E, and K (107-113). However, nicotinamide can affect cellular survival during metabolic dysfunction and impact multiple systems of the body that are particularly affected by aging. Nicotinamide can foster protection during aging and mitochondrial dysfunction (79, 106, 114, 115), neuronal cell injury (103, 104, 116-119), vascular aging processes (29, 73, 101, 120), vascular demise and associated angiogenesis (101, 104, 117, 121-123), and neurodegenerative disorders such as AD (7, 87, 98, 124). Nicotinamide offers protection usually in a specific concentration range (81). Administration of nicotinamide in a range of 5.0 - 25.0 mmol/L can significantly protect neurons during oxidative stress injuries. This concentration range is similar to other injury paradigms in both animal models (125) and in cell culture models (82, 121, 126). It is important to note that elevated concentrations in some experimental models may not offer protection and can be detrimental (108, 127).

5. NICOTINAMIDE AND METABOLIC DYSFUNCTION

5.1. Nicotinamide and diabetes mellitus

Nicotinamide plays a significant role during metabolic dysfunction and DM (29, 72, 73) (Table 1). Nicotinamide may lower insulin resistance and glucose release in combination with other factors to prevent the onset and progression of DM (128-130). Nicotinamide may protect against skeletal muscle atrophy during DM (131) and may reduce inflammation of the brain during DM with the administration of niacin (132). Prior work also has

shown that nicotinamide can maintain normal fasting blood glucose with streptozotocin-induced DM in animal models (133, 134) and inhibit oxidative stress pathways that lead to cell death and apoptosis (121, 135-138). Nicotinamide can significantly improve glucose utilization, prevent excessive lactate production, and improve electrophysiologic capacity in ischemic animal models (139). Oral nicotinamide administration (1200mg/m²/day) protects pancreatic β -cell function and prevents clinical disease in islet-cell antibody-positive first-degree relatives of type-1 DM (140). Nicotinamide administration (25mg/kg) in patients with recent onset type-1 DM combined with intensive insulin therapy for up to two years after diagnosis can significantly reduce HbA_{1c} levels (141). Yet, the duration of nicotinamide administration may influence the efficacy of this agent since long-term administration has been reported to support glucose intolerance in some animal models (93). Prolonged exposure of nicotinamide in other studies was reported to result in impaired pancreatic β -cell function and cell growth (142, 143). Nicotinamide also may inhibit cytochromes P450 and hepatic metabolism (144).

5.2. Nicotinamide and maintenance of mitochondrial function

As previously noted during metabolic disease, nicotinamide is vital for maintaining important cellular energy homeostasis and mitochondrial function (78, 79, 82, 120). Nicotinamide can control mitochondrial function at the level of mitochondrial membrane pore formation to prevent the release of cytochrome c (82, 121, 136). Pretreatment of cells with either nicotinamide alone or in combination with the mitochondrial permeability transition pore inhibitor cyclosporin A prior to an injury paradigm can inhibit mitochondrial membrane depolarization (145, 146). Nicotinamide can block the chemical induction of mitochondrial membrane depolarization during exposure to either *tert*-butylhydroperoxide or atractyloside (104). There are other pathways that nicotinamide may use to maintain cellular metabolic homeostasis through the maintenance of mitochondrial membrane potential (121, 126). Nicotinamide can lead to the phosphorylation of Bad to prevent mitochondrial membrane depolarization and subsequent

cytochrome c release (82, 121, 136), block the assembly of the mitochondrial permeability transition pore complex similar to the action of cyclosporin A (147), or stabilize cellular energy metabolism since the maintenance of mitochondrial membrane potential is an ATP facilitated process (148).

6. NICOTINAMIDE, PATHWAYS OF CELL DEATH, AND AUTOPHAGY

6.1. Apoptotic Cell Death

As a vital modulator of cell survival, nicotinamide oversees pathways of programmed cell death that involves apoptosis (149-151). The apoptotic pathway consists of two distinct phases. The early phase involves the loss of plasma membrane phosphatidylserine (PS) asymmetry (152-158). A later phase results in genomic DNA degradation (156, 159-163). Apoptosis is initiated through a cascade activation of nucleases and proteases that involve caspases (105, 106, 164-167). These processes can influence both the early phase of apoptosis with the loss of plasma membrane PS asymmetry and the later phase that leads to genomic DNA degradation. Loss of membrane PS asymmetry activates inflammatory cells to target, engulf, and remove injured cells (152, 157, 168, 169). If the engulfment by inflammatory cells can be prevented and cells that have membrane PS residues exposed are not removed, then functional cells expressing membrane PS residues can be rescued (62, 160, 170, 171). Yet, once the destruction of cellular DNA occurs, the process is usually not considered to be completely reversible (172).

Nicotinamide can address both phases of apoptotic cell injury. During different cellular injury paradigms, nicotinamide can prevent exposure of membrane PS residues to block inflammatory cell activation (81, 121, 126, 136). In particular, nicotinamide may reduce cardiovascular injury by blocking membrane PS exposure in vascular cells (82, 121), since membrane PS residue externalization in vascular cells can lead to hypercoagulation states (173) and cellular inflammation (174, 175). Nicotinamide may reverse a previously sustained insult (82, 104, 121, 126, 136, 176). Post-treatment strategies with nicotinamide

that can follow apoptotic injury in “real-time” show that cellular injury can be reversed. Nicotinamide can reverse an initial progression of membrane PS inversion and prevent PS exposure (82, 126, 176, 177). These results support the hypothesis that if a cellular injury does not progress to DNA degradation, the injury can be reversible (82, 126, 176, 177).

In relation to apoptotic DNA degradation, nicotinamide prevents apoptotic DNA injury in vascular cells (104, 121), neurons (116, 124, 136, 178), keratinocytes (179), corneal endothelial cells (180, and photoreceptor cells {Kiuchi, 2002 #3733, 181). Nicotinamide also can inhibit DNA replication in some cell systems (182). Dependent upon the cellular conditions, nicotinamide may not be able to prevent DNA degradation (87). During periods of acidosis-induced cellular toxicity that involve decreased pH, nicotinamide cannot prevent cellular injury during intracellular acidification (126).

6.2. Autophagy

Autophagy is a process that recycles components of the cytoplasm in cells for tissue remodeling (183-185) (Table 1). As a result, it eliminates non-functional organelles (24, 149, 151, 186, 187). Macroautophagy recycles organelles and sequesters cytoplasmic proteins and organelles into autophagosomes. Autophagosomes subsequently combine with lysosomes for degradation and recycling (188, 189). Microautophagy consists of lysosomal membranes invagination for the sequestration and digestion of cytoplasmic components (8). Chaperone-mediated autophagy requires cytosolic chaperones to transport cytoplasmic components across lysosomal membranes (67, 190).

Similar to nicotinamide, autophagy is involved with clinical aging pathways (12, 105, 184). Studies with *Drosophila* show that neural aggregate accumulation observed with aging is linked to a reduction in the autophagy pathway. These neural aggregates lead to behavior impairments that can be resolved with the maintenance of autophagy pathways in neurons (191). Autophagy also is involved in a number of other disorders that may be tied to aging such as dementia (40, 192-196), AD (7,




Figure 2. mTOR oversight of autophagy and apoptosis. mTOR is the principal component of the protein complexes mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2). mTORC1 is composed of Raptor, the proline rich Akt substrate 40 kDa (PRAS40), Deptor (DEP domain-containing mTOR interacting protein), and mammalian lethal with Sec13 protein 8, termed mLST8 (214). mTORC2 is composed of Rictor, mLST8, Deptor, the mammalian stress-activated protein kinase interacting protein (mSIN1), and the protein observed with Rictor-1 (Protor-1). Autophagy activity can be controlled through mTOR since activation of autophagy occurs during the inhibition of mTOR. As an example, mTOR inhibition also may be required for maintaining a balance between pancreatic β -cell proliferation and cell size. Yet, mTOR activation can be beneficial at times since mTOR activation protects pancreatic β -cells against cholesterol-induced apoptosis, reduces glucolipotoxicity, and results in increased neuronal cell survival in cellular models of diabetes mellitus. These observations demonstrate that a fine balance in activity is required for mTOR, autophagic, and apoptotic pathways.

12, 39, 40, 193, 197-201), Huntington's disease (HD) (172, 202-204), and DM (21, 27, 39, 40, 62, 193, 205).

Nicotinamide has been tied to autophagic pathways, especially as an inhibitor of sirtuin pathways, such as those involved with silent mating type information regulation 2 homolog 1 (*Saccharomyces cerevisiae*) (SIRT1) (7, 16). Nicotinamide can lead to the induction of delayed autophagy and decreased survival in cancer cells (206). Mitochondrial autophagy can result in an increased NAD⁺/NADH ratio during nicotinamide administration (93, 105, 207) and in some cases induction of autophagy can affect mitochondrial mass (196, 208, 209). Chronic administration of nicotinamide can result in skeletal muscle autophagy (93). Nicotinamide has been shown to protect against palmitate-induced hepatotoxicity via SIRT1-dependent induction of autophagy (210).

7. NICOTINAMIDE AND THE MECHANISTIC TARGET OF RAPAMYCIN

7.1. Nicotinamide and mTOR

Through autophagy, nicotinamide has been shown to rely upon the pathways of the mechanistic target of rapamycin (mTOR) (Table 1). For example, nicotinamide can protect hypoxic myocardial cells through the induction of autophagy and the modulation of mTOR pathways (211). mTOR, a 289-kDa serine/threonine protein kinase, is increasingly being recognized as a critical pathway for nicotinamide given the ability of this vitamin to control cellular metabolism and the programmed death pathways of autophagy and apoptosis. mTOR also is known as the mammalian target of rapamycin and the FK506-binding protein 12-rapamycin complex-associated protein 1 (203, 212) and is encoded by a single gene *FRAP1* (213-215). The target of rapamycin (TOR) was initially discovered in *Saccharomyces cerevisiae* with the genes *TOR1* and *TOR2* (216). Using rapamycin-resistant TOR mutants, *TOR1* and *TOR2* are now known to encode the Tor1 and Tor2 isoforms in yeast (217). The compound rapamycin is a macrolide antibiotic in *Streptomyces hygroscopicus* that blocks TOR and mTOR activity (24).

mTOR serves as the principal component of the protein complexes mTOR Complex 1 (mTORC1) and mTOR Complex 2 (mTORC2) (218-220) (Figure 2). Rapamycin prevents mTORC1 activity by binding to immunophilin FK-506-binding protein 12 (FKBP12) that attaches to the FKBP12 - rapamycin-binding domain (FRB) at the carboxy (C) -terminal of mTOR to interfere with the FRB domain of mTORC1 (221). The mechanism of how rapamycin blocks mTORC1 activity with the interaction of the domain of FRB is not entirely clear. One pathway may involve allosteric changes on the catalytic domain as well as the inhibition of phosphorylation of protein kinase B (Akt) and p70 ribosomal S6 kinase (p70S6K) (222). mTORC1 is more sensitive to inhibition by rapamycin than mTORC2, but chronic administration of rapamycin can inhibit mTORC2 activity as a result of the disruption of the assembly of mTORC2.

7.2. mTOR as a component of mTORC1

mTORC1 is composed of Raptor, the proline rich Akt substrate 40 kDa (PRAS40), Deptor (DEP domain-containing mTOR interacting protein), and mammalian lethal with Sec13 protein 8, termed mLST8 (mLST8) (216). mTORC1 binds to its constituents through the protein Ras homologue enriched in brain (Rheb) that phosphorylates the Raptor residue serine⁸⁶³ and other residues that include serine⁸⁵⁹, serine⁸⁵⁵, serine⁸⁷⁷, serine⁶⁹⁶, and threonine⁷⁰⁶ (223). The inability to phosphorylate serine⁸⁶³ limits mTORC1 activity, as shown using a site-direct mutation of serine⁸⁶³ (224). mTOR can control Raptor activity which can be blocked by rapamycin (224). Deptor, an inhibitor, blocks mTORC1 activity by binding to the FAT domain (FKBP12 -rapamycin-associated protein (FRAP), ataxia-telangiectasia (ATM), and the transactivation/transformation domain-associated protein) of mTOR. If the activity of Deptor is suppressed, Akt, mTORC1, and mTORC2 activities are increased (225). PRAS40 blocks mTORC1 activity by preventing the association of p70 ribosomal S6 kinase (p70S6K) and the eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4EBP1) with Raptor (188, 226). mTORC1 is active once PRAS40 is phosphorylated by Akt. This releases PRAS40 from Raptor to sequester PRAS40 in the cytoplasm of the cell with the docking protein 14-3-3 (227-231). mLST8, in contrast to Deptor and PRAS40, promotes mTOR kinase activity. This involves the binding of p70S6K and 4EBP1 to Raptor (232). In relation to cellular metabolism, mLST8 also controls insulin signaling through the mammalian forkhead transcription factor FoxO3 (67, 233). mLST8 is also necessary for Akt and protein kinase C- α (PKC α) phosphorylation and is required for Rictor to associate with mTOR (233).

7.3. mTOR as a component of mTORC2

mTORC2 is composed of Rictor, mLST8, Deptor, the mammalian stress-activated protein kinase interacting protein (mSIN1), and the protein observed with Rictor-1 (Protor-1) (188, 213). mTORC2 oversees cytoskeleton remodeling through PKC α and cell migration through the Rac guanine nucleotide exchange factors P-Rex1 and P-Rex2 and

through Rho signaling (234). mTORC2 promotes activity of protein kinases that includes glucocorticoid induced protein kinase 1 (SGK1), a member of the protein kinase A/protein kinase G/protein kinase C (AGC) family of protein kinases. Protor-1, a Rictor-binding subunit of mTORC2, activates SGK1 (235, 236). The kinase domain of mTOR phosphorylates mSIN1 and blocks lysosomal degradation of this protein. Rictor and mSIN1 also phosphorylate Akt at serine⁴⁷³ and foster threonine³⁰⁸ phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) to enhance cell survival.

7.4. mTOR and AMP activated protein kinase

Both mTORC1 and mTORC2 are tied to metabolic cellular regulation. These pathways are closely linked to the AMP activated protein kinase (AMPK) (16, 56, 237, 238) (Table 1). mTORC1 is associated with metabolic cellular pathways and can stimulate lipogenesis and fat storage (15, 239), may increase pancreatic β -cell mass (240), and can improve glucose homeostasis (241). In the presence of other cellular pathways and systems such as with SIRT1, mTORC1 activity may require inhibition to preserve glucose homeostasis (242). mTORC2 also may be necessary to maintain glucose homeostasis (15), since loss of this pathway can promote severe hyperglycemia (243). Impairment in mTORC2 signaling can result in oxidative damage and insulin resistance (244). mTORC2 signaling also plays a significant role for the maintenance of pancreatic β -cell proliferation and mass (245).

In regards to AMPK, AMPK blocks mTORC1 activity through the hamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex that inhibits mTORC1 (246, 247) (Figure 3). Control of the TSC1/TSC2 complex also is controlled through phosphoinositide 3-kinase (PI 3-K), Akt, and its phosphorylation of TSC2. Extracellular signal-regulated kinases (ERKs), protein p90 ribosomal S6 kinase 1 (RSK1), and glycogen synthase kinase -3 β (GSK-3 β) can modulate the activity of the TSC1/TSC2 complex as well. TSC2 functions as a GTPase-activating protein (GAP) that converts G protein Rheb (Rheb-GTP) into the inactive GDP-bound form (Rheb-GDP). Once




Figure 3. AMPK affects multiple pathways through mTOR signaling. AMP activated protein kinase (AMPK) inhibits mTOR Complex 1 (mTORC1) activity through the hamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2) complex. During periods of hyperglycemia, AMPK activity increases basal autophagy activity and maintains endothelial cell survival. In addition, AMPK can regulate apoptosis and autophagy during vascular disease and oxidative stress cell injury. Agents used to treat diabetes mellitus, such as biguanides and metformin, rely upon AMPK to restore cellular function. Through metformin, AMPK can be activated, leads to the induction of autophagy, and protects against cell apoptosis. Metformin also has been shown to limit lipid peroxidation in the brain and spinal cord and decrease caspase activity during toxic insults.

Rheb-GTP is active, Rheb-GTP associates with Raptor to control the binding of 4EBP1 to mTORC1 and increase mTORC1 activity (248). AMPK can phosphorylate TSC2 to increase GAP activity to change Rheb-GTP into the inactive Rheb-GDP and block mTORC1 activity (249).

8. NICOTINAMIDE, mTOR, AMPK, AND METABOLIC DISORDERS

8.1. mTOR and metabolic function

mTOR pathways are intimately tied to cellular metabolic function (24, 250). mTOR activation protects pancreatic β -cells against cholesterol-induced apoptosis (251), reduces glucolipotoxicity (252), and results in increased neuronal cell survival in cellular models of DM (253). mTOR activity controls insulin signaling in experimental models of AD and maintains astrocyte viability (254), promotes the differentiation of adipocytes (255), preserves endothelial cell function during hyperglycemia (54), and maintains glucose homeostasis (241). mTOR also may offer protection

as a component of the Mediterranean diet as a focus on obesity in the population. The diet has been reported to reduce A β toxicity in astrocytes through enhanced Akt activity by consumption of polyphenol of olives and olive oil that ultimately could prevent the onset or progression of AD (254). In patients with metabolic syndrome, mTOR activation has been found to be diminished, suggesting that loss of mTOR may lead to insulin resistance and the increased risk of vascular thrombosis (256). In addition, growth factors that offer cellular protection against oxidative stress, such as insulin growth factor-1 (IGF-1) (257, 258) and erythropoietin (EPO) (259-270), may employ mTOR pathways as well (16, 227, 271-276). For example, EPO utilizes components of the mTOR pathway, such as PRAS40 and Akt, to enhance cell survival (227, 272, 273, 276) and limit toxic cellular environments (275, 277-279). EPO also plays a significant role as a potential cellular protectant during aging (280) and DM with the modulation of mTOR pathways, in part, to maintain cellular survival (24, 62, 73, 74, 175, 281-286).

8.2. Nicotinamide and the downstream pathways of mTOR

Nicotinamide and mTOR downstream pathways also play a critical role during metabolic dysfunction (Table 1). For example, mTOR pathway activation with p70S6K and 4EBP1 can improve insulin secretion in pancreatic β -cells and increase resistance to β -cell streptozotocin toxicity and obesity in mice (240). Both p70S6K and 4EBP1 in the mTOR pathway are also utilized by nicotinamide to protect against radiation-induced apoptosis (179).

Interestingly, nicotinamide has a close relationship with poly (ADP-ribose) polymerase (PARP) (81, 87) that is also tied to mTOR and Akt (287, 288). PARP is a nuclear protein that binds to DNA strand breaks and cleaves NAD⁺ into nicotinamide and ADP-ribose. PARP catalyzes the synthesis of poly (ADP-ribose) from its substrate NAD⁺, which can foster the process of DNA repair (289). Nicotinamide can prevent PARP degradation and allow for DNA repair through the direct inhibition of caspase 3 (121, 126, 136). However, elevated concentrations of nicotinamide can lead to PARP degradation and apoptotic injury (290). Under some

circumstances, a reduction in PARP activity may enhance neuronal cell survival, such as during cerebral ischemia (72). Prevention of NAD⁺ depletion during enhanced PARP activity also has been demonstrated to prevent cellular lysis during oxidative stress. In experimental studies of AD, PARP is present in the frontal and temporal cortex more frequently than in controls, suggesting that increased levels of functional PARP enzyme are present to potentially lead to the depletion of NAD⁺ stores (291). Reduction of PARP activity may be protective against oxidative stress and A β (124). Furthermore, recent work illustrates that inhibition of the mTOR and PARP axis has protective effects on photoreceptors against visible-light-induced parthanatos (288), a form of programmed cell death that is distinct from other cell death processes such as necrosis and apoptosis and a PARP-1 dependent cell death.

Nicotinamide also can protect hypoxic cardiomyocytes and reduce intracellular mitochondrial stress through activation of the AMPK pathway (292). During periods of reduced dietary intake that may increase lifespan (116), AMPK activation can shift to beneficial oxidative metabolism (293) and has been shown to limit ischemic brain damage in diabetic animal models (294). AMPK activation also can strengthen memory retention in models of AD and DM (237), may assist with the elimination of β -amyloid (A β) in the brain (295), facilitate tau clearance (201), and limit chronic inflammation in the nervous system (12, 247, 296). AMPK can limit insulin resistance (297) and protect endothelial progenitor cells during periods of hyperglycemia (56) similar to the vascular protective properties of nicotinamide (104, 121, 298).

AMPK controls metabolic pathways through apoptosis and autophagy (Figure 3). During periods of hyperglycemia, AMPK activity can increase basal autophagy activity (149, 172) and maintain endothelial cell survival (54, 299). AMPK can regulate apoptosis and autophagy during coronary artery disease (300), endothelial dysfunction during hyperglycemia (54), and oxidative stress cell injury (301, 302). Anti-senescence activity also can be fostered through mTOR inhibition, AMPK activation, and the acceleration of autophagic flux

(303). In addition to nicotinamide, other agents rely upon the ability of AMPK to modulate cellular metabolism. Agents used to treat DM, such as biguanides and metformin, use mTOR, AMPK, and autophagy to restore cellular function. Metformin inhibits mTOR activity, promotes autophagy, and may function at times in an AMPK-independent manner (304). Other reports note that through metformin, AMPK is activated, restores the induction of autophagy, and protects against diabetic cardiac cell apoptosis (305). Metformin also has been shown to limit lipid peroxidation in the brain and spinal cord and decrease caspase activity during toxic insults (306). Such results may be associated with the ability of autophagic pathways to limit oxidative stress under some circumstances (27, 307).

8.3. Nicotinamide and the Necessary Modulation of Autophagy with mTOR

Interestingly, similar to nicotinamide having optimal dose concentrations for beneficial biological outcomes, autophagy also requires specific modulation of activity (Table 1). Under some circumstances, inhibition of autophagy may be required to achieve a benefit. In some experimental models of AD, autophagy activation can be one factor that leads to neuronal cell death (200). Increased activity of autophagy also can result in significant loss of cardiac and liver tissue in diabetic rats during attempts to achieve glycemic control through diet modification (77). Advanced glycation end products (AGEs), agents that can result in complications during DM, have also been shown to result in the activation of autophagy and vascular smooth muscle proliferation that can lead to atherosclerosis (308) and cardiomyopathy (309). Autophagy activation also can injure endothelial progenitor cells, lead to mitochondrial oxidative stress (310), and block angiogenesis (311) during periods of elevated glucose levels. Chronic inflammatory conditions, such as lichen planus, also have been linked to mTOR inhibition and autophagy activation (312). Interneuron progenitor growth in the brain relies upon mTOR activity with the inhibition of autophagy (313). During ischemic stroke in rodents, inhibition of autophagy may also limit infarct size and rescue cerebral neurons (314).

One mechanism for the modulation of autophagy activity may be through mTOR given that activation of autophagy occurs during the inhibition of mTOR (16, 315, 316). At times, inhibition of mTOR during DM can be beneficial and provide protection such as during cerebral ischemia (294). mTOR inhibition also may be necessary for maintaining a balance between pancreatic β -cell proliferation and cell size (245). Yet, other studies suggest that loss of mTOR activity can be detrimental. During mTOR inhibition with rapamycin, reduced β -cell function, insulin resistance, and decreased insulin secretion can promote the progression of DM (317). Decreased activity of mTOR also has been shown to increase mortality in a mouse model of DM (318). Translocation of glucose transporters to the plasma membrane in skeletal muscle can be blocked in the absence of mTOR activity (319). These studies may suggest that there may be a biological feedback for mTOR, such as through AMPK inhibition, to prevent excessive mTOR activity and allow for the activation of autophagy. For example, if mTOR activity is allowed to go unchecked with the down-regulation of AMPK activity during experimental studies, mTOR and p70S6K can lead to glucose intolerance by inhibiting the insulin receptor substrate 1 (IRS-1) (320).

Nicotinamide may require a close modulation of autophagy and mTOR to offer protection during disorders such as DM. Nicotinamide can offer cellular protection through autophagy (211) that requires inhibition of mTOR activity to allow for the activation of autophagy. Dysregulation of autophagy can potentially lead to the progression of cognitive loss with AD and the induction of DM (39). At least 33 autophagy-related genes (*Atg*) that have been identified in yeast with 40 autophagy-related genes involved in autophagosomes formation (185) that can affect multiple disorders including DM (15, 67, 321). *Atg1*, *Atg13* (also known as *Apg13*), and *Atg17* are associated with the PI 3-K, Akt, and TOR pathways (149). Autophagy haploinsufficiency with deletion of *Atg7* gene in mouse models of obesity leads to increased insulin resistance with elevated lipids and inflammation (322). Loss of autophagic proteins *Atg7*, *Atg5*, and *LC3* also can be responsible for diabetic nephropathy (323). Autophagy can be

beneficial at the cellular level. Autophagy can remove misfolded proteins and eliminate non-functioning mitochondria to maintain β -cell function and prevent the onset of DM (324). Exercise in mice has been shown to promote the induction of autophagy and regulate glucose homeostasis (325). Autophagy also can improve insulin sensitivity during high fat diets in mice (297) and may be protective to microglia during acute glucose fluctuations (193).

It is important to recognize that in a number of circumstances, autophagy and apoptosis are closely linked to alter cellular survival. Inhibition of mTOR activity with activation of autophagy can reduce markers of senescence and aging in the skin of patients (326). Blockade of mTOR also can prevent aging and cell injury with extension of cell longevity through AMPK in endothelial cells (303). Additional work suggests that a balance is required during embryogenesis for autophagy and apoptosis that can affect body axis formation (327). Inhibition of mTOR pathways can trigger autophagy activation and affect tumor cell growth through the inhibition of apoptosis (328, 329). Yet, dependent upon the balance between autophagy and apoptotic pathways, other studies have shown that with nicotinamide one can block apoptosis in human colon cancer cells through the activation of autophagy (207). These studies support the premise that the balance between autophagy and apoptosis requires careful modulation to foster a desired biological outcome with nicotinamide.

9. FUTURE PERSPECTIVES FOR NICOTINAMIDE

Metabolic disorders, such as DM, pose a significant risk for the global population and contribute to the large percentage of deaths that are the result of NCDs (1, 2) (Table 1). Of even greater concern is the observation that of the over forty million people that die each year from NCDs, fifteen million individuals are between the ages of thirty and sixty-nine years old. In addition, NCDs affect a greater proportion of the population in low and middle-income countries. As the world's population continues to age, life expectancy has been increasing that has occurred in parallel to the rise in NCDs (Figure 1).

As significant NCDs, metabolic disorders and DM are seen as critical targets to address and develop innovative strategies to limit death and disability for the global population afflicted by these disorders. Almost eighty percent of adults with DM reside in low- and middle-income countries and the care for patients with DM consumes more than seventeen percent of the Gross Domestic Product in the US (18). Furthermore, DM is believed to affect seven hundred million people by the year 2045 (17). DM affects all systems of the body that can involve the nervous system, cardiovascular system, and immune system. DM also alters new tissue generation and repair. Current conventional therapies for metabolic disorders and DM such as early recognition of disease onset, treatment with nutrition, and administration of pharmacological care can offer some degree of protection and may slow the progression of DM. However, treatments that lead to tight serum glucose control do not always resolve the eventual complications from DM and may pose potential risks that can decrease organ mass through autophagy. Given these concerns, innovative and novel strategies for metabolic disorders that involve DM are highly warranted for rapid development. Nicotinamide and the pathways associated with mTOR, mTORC1, mTORC2, AMPK, autophagy, and apoptosis fill this void to offer new avenues for the treatment of metabolic disorders.

Nicotinamide offers a partially unique perspective as a cellular protectant since it can foster cellular survival against oxidative stress not only during aging processes (72, 105, 114) and life span extension (29, 92, 116), but also during metabolic dysfunction (72, 88, 128, 131, 330). Nicotinamide can reverse a previously sustained insult by limiting the onset and progression of membrane PS exposure and apoptotic cell death. During DM, nicotinamide maintains cellular energy homeostasis and mitochondrial function, lowers insulin resistance and glucose release, protects against skeletal muscle atrophy, reduces inflammation of the brain, protects pancreatic β -cell function, improves glucose utilization, and prevents excessive lactate production. Nicotinamide employs mTOR pathways such that it can prevent myocardial cell death during hypoxia through the oversight of mTOR and autophagy. As a result, nicotinamide relies upon the

inverse relationship between mTOR and autophagy pathways to control cellular survival. Similar to nicotinamide, mTOR activation can protect pancreatic β -cells and maintain glucose homeostasis. Through autophagy activation, the mTOR related pathway of AMPK can increase basal autophagy activity to prevent cellular apoptosis during DM. In addition, nicotinamide has been shown to protect hypoxic cardiomyocytes and reduce intracellular mitochondrial stress through activation of AMPK and autophagic pathways. Chronic administration of nicotinamide can activate skeletal muscle autophagy as a potential protective response to lipotoxicity.

However, there are a number of hurdles to consider for the targeting of nicotinamide, mTOR, and autophagy for the treatment of metabolic disorders. Nicotinamide appears to offer cellular protection during metabolic dysfunction in specific concentration ranges. Nicotinamide may protect against skeletal muscle atrophy during DM and can reduce inflammation of the brain during diabetes with the administration of niacin. Yet, the duration of nicotinamide administration may influence the efficacy of this agent since long-term administration has been reported to support glucose intolerance in some animal models and prolonged exposure of nicotinamide can result in impaired β -cell function and cell growth (142, 143). The acute and chronic levels of NAD^+ that are generated may be vital to determine cellular survival. Similar to nicotinamide, autophagy may require critical modulation of activity. Nicotinamide can protect against palmitate-induced hepatotoxicity via SIRT1-dependent induction of autophagy. In addition, autophagy can improve insulin sensitivity during high fat diets and may protect microglia during acute glucose fluctuations (193). Yet, autophagy activation also can injure endothelial progenitor cells, lead to mitochondrial oxidative stress, and block angiogenesis during periods of elevated glucose levels. mTOR, as a pathway that is inhibited during autophagy activation, may be a critical factor for nicotinamide to maintain cell viability during metabolic dysfunction. In some studies, loss of mTOR activity can be detrimental and result in reduced β -cell function, insulin resistance, and decreased insulin secretion that foster the progression of DM. In other scenarios, inhibition of

mTOR during DM can be beneficial and provide protection such as during cerebral ischemia and may be necessary for maintaining a balance between pancreatic β -cell proliferation and cell size. Given these observations, it becomes clear that targeting nicotinamide as an effective agent to treat metabolic disorders may require careful scrutiny of the fine balance in activity required for mTOR and autophagic pathways. Additional investigations are warranted and would be highly advantageous to examine the intricate pathways of the vitamin nicotinamide and how they can be effectively utilized to provide innovative clinical strategies for metabolic dysfunction and DM.

10. ACKNOWLEDGMENTS

This research was supported by the following grants to Kenneth Maiese: American Diabetes Association, American Heart Association, NIH NIEHS, NIH NIA, NIH NINDS, and NIH ARRA.

11. REFERENCES

1. World Health Organization: Description of the global burden of NCDs, their risk factors and determinants. *Global status report on noncommunicable diseases 2010*(April), 1-176 (2011)
2. World Health Organization: Global action plan on the public health response to dementia 2017-2025, 1-44 (2017)
3. K. Maiese: Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer's Disease. *Curr Neurovasc Res*, 15(4) (2018)
DOI: 10.2174/1567202616666181-128120003
4. K. Maiese: Cutting through the Complexities of mTOR for the Treatment of Stroke. *Curr Neurovasc Res*, 11(2), 177-186 (2014)
5. A. M. Minino: Death in the United States, 2011. *NCHS Data Brief*(115), 1-8 (2013)
6. A. Hayutin: Global demographic shifts create challenges and opportunities. *PREA Quarterly*, (Fall), 46-53 (2007)
7. K. Maiese: SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer. *World J Stem Cells*, 7(2), 235-42 (2015)
DOI: 10.4252/wjsc.v7.i2.235
8. K. Maiese: Programming apoptosis and autophagy with novel approaches for diabetes mellitus. *Curr Neurovasc Res*, 12(2), 173-88 (2015)
9. E. Diamanti-Kandarakis, M. Datillo, D. Macut, L. H. Duntas, E. Gonos, D. Goulis, C. Kanaka-Gantenbein, M. Kapetanou, E. G. Koukkou, I. Lambrinoudaki, M. Michalaki, S. Nader-Eftekhari, R. Pasquali, M. Peppas, M. Tzanela, E. Vassilatou and A. Vryonidou: Mechanisms in Endocrinology: Aging and Anti-aging Endocrinology: A Combo - Endocrinology Overview. *Eur J Endocrinol*, 176(6), R283-R308 (2017)
DOI: 10.1530/eje-16-1061
10. D. Y. Fann, G. Y. Ng, L. Poh and T. V. Arumugam: Positive effects of intermittent fasting in ischemic stroke. *Exp Gerontol*, 89, 93-102 (2017)
DOI: 10.1016/j.exger.2017.01.014
11. O. Lushchak, O. Strilbytska, V. Piskovatska, K. B. Storey, A. Koliada and A. Vaiserman: The role of the TOR pathway in mediating the link between nutrition and longevity. *Mech Ageing Dev*, 164, 127-138 (2017)
DOI: 10.1016/j.mad.2017.03.005
12. K. Maiese: Moving to the Rhythm with Clock (Circadian) Genes, Autophagy,

- mTOR, and SIRT1 in Degenerative Disease and Cancer. *Curr Neurovasc Res*, 14(3), 299-304 (2017)
DOI: 10.2174/1567202614666-170718092010
13. R. Stefanatos and A. Sanz: The role of mitochondrial ROS in the aging brain. *FEBS Lett*, 592(5), 743-758 (2018)
DOI: 10.1002/1873-3468.12902
14. V. V. Klimontov, D. M. Bulumbaeva, O. N. Fazullina, A. P. Lykov, N. P. Bgatova, N. B. Orlov, V. I. Konenkov, A. F. H. Pfeiffer, O. Pivovarova-Ramich and N. Rudovich: Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. *J Cell Commun Signal* (2019)
DOI: 10.1007/s12079-019-00536-4
15. K. Maiese: Novel nervous and multi-system regenerative therapeutic strategies for diabetes mellitus with mTOR. *Neural Regen Res*, 11(3), 372-85 (2016)
DOI: 10.4103/1673-5374.179032
16. K. Maiese: Impacting dementia and cognitive loss with innovative strategies: mechanistic target of rapamycin, clock genes, circular non-coding ribonucleic acids, and Rho/Rock. *Neural Regen Res*, 14(5), 773-774 (2019)
DOI: 10.4103/1673-5374.249224
17. International Diabetes Federation: Diabetes. *IDF Diabetes Atlas*(9th Edition) (2019)
18. Centers for Medicare and Medicaid Services: National Health Expenditure Projections 2018-2027. www.cms.gov (2019)
19. S. R. Haldar, A. Chakrabarty, S. Chowdhury, A. Haldar, S. Sengupta and M. Bhattacharyya: Oxidative stress-related genes in type 2 diabetes: association analysis and their clinical impact. *Biochem Genet*, 53(4-6), 93-119 (2015)
DOI: 10.1007/s10528-015-9675-z
20. G. Jia, A. R. Aroor, L. A. Martinez-Lemus and J. R. Sowers: Invited Review: Over-nutrition, mTOR Signaling and Cardiovascular Diseases. *Am J Physiol Regul Integr Comp Physiol*, 307(10), R1198-206 (2014)
DOI: 10.1152/ajpregu.00262.2014
21. K. Maiese: New Insights for Oxidative Stress and Diabetes Mellitus. *Oxid Med Cell Longev*, 2015(2015:875961) (2015)
DOI: 10.1155/2015/875961
22. Q. Ye and J. F. Fu: Paediatric type 2 diabetes in China-Pandemic, progression, and potential solutions. *Pediatr Diabetes*, 19(1) (2018)
DOI: 10.1111/pedi.12517
23. M. I. Harris and R. C. Eastman: Early detection of undiagnosed diabetes mellitus: a US perspective. *Diabetes Metab Res Rev*, 16(4), 230-6 (2000)
24. K. Maiese: mTOR: Driving apoptosis and autophagy for neurocardiac complications of diabetes mellitus. *World J Diabetes*, 6(2), 217-24 (2015)
DOI: 10.4239/wjd.v6.i2.217
25. K. Maiese, Z. Z. Chong and Y. C. Shang: Mechanistic insights into diabetes mellitus and oxidative stress. *Curr Med Chem*, 14(16), 1729-38 (2007)
26. I. Barchetta, F. A. Cimini, G. Ciccarelli, M. G. Baroni and M. G. Cavallo: Sick fat: the

- good and the bad of old and new circulating markers of adipose tissue inflammation. *J Endocrinol Invest* (2019)
DOI: 10.1007/s40618-019-01052-3
27. K. Maiese: Erythropoietin and diabetes mellitus. *World J Diabetes*, 6(14), 1259-73 (2015)
DOI: 10.4239/wjd.v6.i14.1259
28. A. R. Wang, X. Q. Yan, C. Zhang, C. Q. Du, W. J. Long, D. Zhan, J. Ren and X. P. Luo: Characterization of Wnt1-inducible Signaling Pathway Protein-1 in Obese Children and Adolescents. *Curr Med Sci*, 38(5), 868-874 (2018)
DOI: 10.1007/s11596-018-1955-5
29. K. Maiese, Z. Z. Chong, Y. C. Shang and J. Hou: Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus. *J Clin Pharmacol*, 51(2), 128-52 (2011)
30. M. Cernea, W. Tang, H. Guan and K. Yang: Wisp1 mediates Bmp3-stimulated mesenchymal stem cell proliferation. *J Mol Endocrinol*, 56(1), 39-46 (2016)
DOI: 10.1530/jme-15-0217
31. I. Curjuric, M. Imboden, P. O. Bridevaux, M. W. Gerbase, M. Haun, D. Keidel, A. Kumar, M. Pons, T. Rochat, T. Schikowski, C. Schindler, A. von Eckardstein, F. Kronenberg and N. M. Probst-Hensch: Common SIRT1 variants modify the effect of abdominal adipose tissue on aging-related lung function decline. *Age (Dordr)*, 38(3), 52 (2016)
DOI: 10.1007/s11357-016-9917-y
32. J. H. Hill, C. Solt and M. T. Foster: Obesity associated disease risk: the role of inherent differences and location of adipose depots. *Horm Mol Biol Clin Invest* (2018)
DOI: 10.1515/hmbci-2018-0012
33. Z. Liu, L. Gan, T. Zhang, Q. Ren and C. Sun: Melatonin alleviates adipose inflammation through elevating alpha-ketoglutarate and diverting adipose-derived exosomes to macrophages in mice. *J Pineal Res*, 64(1), 12455 (2018)
DOI: 10.1111/jpi.12455
34. K. Maiese: Picking a bone with WISP1 (CCN4): new strategies against degenerative joint disease. *J Transl Sci*, 1(3), 83-85 (2016)
35. J. Mehta, S. Rayalam and X. Wang: Cytoprotective Effects of Natural Compounds against Oxidative Stress. *Antioxidants (Basel)*, 7(10) (2018)
DOI: 10.3390/antiox7100147
36. M. Albiero, N. Poncina, M. Tjwa, S. Ciciliot, L. Menegazzo, G. Ceolotto, S. Vigili de Kreutzenberg, R. Moura, M. Giorgio, P. Pelicci, A. Avogaro and G. P. Fadini: Diabetes causes bone marrow autonomic neuropathy and impairs stem cell mobilization via dysregulated p66Shc and Sirt1. *Diabetes*, 63(4), 1353-65 (2014)
DOI: 10.2337/db13-0894
37. M. B. Gomes and C. A. Negrato: Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. *Diabetol Metab Syndr*, 6(1), 80 (2014)
DOI: 10.1186/1758-5996-6-80
38. A. Gomez-Brouchet, N. Blaes, L. Mouldous, O. Fourcade, I. Tack, B. Frances, J. P. Girolami and V. Minville: Beneficial effects of levobupivacaine regional anaesthesia on postoperative opioid induced hyperalgesia in diabetic mice. *J Transl Med*, 13(1), 208 (2015)
DOI: 10.1186/s12967-015-0575-0

39. L. Caberlotto, T. P. Nguyen, M. Lauria, C. Priami, R. Rimondini, S. Maioli, A. Cedazo-Minguez, G. Sita, F. Morroni, M. Corsi and L. Carboni: Cross-disease analysis of Alzheimer's disease and type-2 Diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. *Sci Rep*, 9(1), 3965 (2019)
DOI: 10.1038/s41598-019-39828-5
40. M. Su, K. Naderi, N. Samson, I. Youssef, L. Fulop, Z. Bozso, S. Laroche, B. Delatour and S. Davis: Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology. *Mol Neurobiol* (2019)
DOI: 10.1007/s12035-019-1475-8
41. K. Maiese, Z. Z. Chong, Y. C. Shang and J. Hou: FoxO proteins: cunning concepts and considerations for the cardiovascular system. *Clin Sci (Lond)*, 116(3), 191-203 (2009)
DOI: 10.1042/CS20080113
42. P. C. Tang, Y. F. Ng, S. Ho, M. Gyda and S. W. Chan: Resveratrol and cardiovascular health--promising therapeutic or hopeless illusion? *Pharmacol Res*, 90, 88-115 (2014)
DOI: 10.1016/j.phrs.2014.08.001
43. L. Xiang, P. N. Mittwede and J. S. Clemmer: Glucose Homeostasis and Cardiovascular Alterations in Diabetes. *Compr Physiol*, 5(4), 1815-39 (2015)
DOI: 10.1002/cphy.c150001
44. Y. J. Xu, P. S. Tappia, N. S. Neki and N. S. Dhalla: Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. *Heart Fail Rev*, 19(1), 113-21 (2014)
DOI: 10.1007/s10741-013-9379-6
45. T. Yao, T. Fujimura, K. Murayama, K. Okumura and Y. Seko: Oxidative Stress-Responsive Apoptosis Inducing Protein (ORAIP) Plays a Critical Role in High Glucose-Induced Apoptosis in Rat Cardiac Myocytes and Murine Pancreatic beta-Cells. *Cells*, 6(4) (2017)
DOI: 10.3390/cells6040035
46. M. Hadamitzky, A. Herring, J. Kirchhof, I. Bendix, M. J. Haight, K. Keyvani, L. Luckemann, M. Unterobderdorster and M. Schedlowski: Repeated systemic treatment with rapamycin affects behavior and amygdala protein expression in rats. *Int J Neuropsychopharmacol* (2018)
DOI: 10.1093/ijnp/pyy017
47. Z. M. Ignacio, G. Z. Reus, C. O. Arent, H. M. Abelaira, M. R. Pitcher and J. Quevedo: New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. *Br J Clin Pharmacol*, 82(5), 1280-1290 (2016)
DOI: 10.1111/bcp.12845
48. M. Di Rosa and L. Malaguarnera: Chitotriosidase: A New Inflammatory Marker in Diabetic Complications. *Pathobiology*, 83(4), 211-9 (2016)
DOI: 10.1159/000443932
49. K. Maiese, Z. Z. Chong, J. Hou and Y. C. Shang: Erythropoietin and oxidative stress. *Curr Neurovasc Res*, 5(2), 125-42 (2008)
50. J. Tulsulkar, S. E. Nada, B. D. Slotterbeck, M. F. McInerney and Z. A. Shah: Obesity and hyperglycemia lead to impaired post-ischemic recovery after permanent ischemia in mice. *Obesity (Silver Spring)*, 24(2), 417-23 (2015)
DOI: 10.1002/oby.21388

51. F. H. Xiao, Y. H. He, Q. G. Li, H. Wu, L. H. Luo and Q. P. Kong: A genome-wide scan reveals important roles of DNA methylation in human longevity by regulating age-related disease genes. *PLoS One*, 10(3), e0120388 (2015)
DOI: 10.1371/journal.pone.0120388
52. L. Arildsen, J. V. Andersen, H. S. Waagepetersen, J. B. D. Nissen and M. Sheykhzade: Hypermetabolism and impaired endothelium-dependent vasodilation in mesenteric arteries of type 2 diabetes mellitus db/db mice. *Diab Vasc Dis Res*, 16(6), 1479164119865885 (2019)
DOI: 10.1177/1479164119865885
53. S. Ding, Y. Zhu, Y. Liang, H. Huang, Y. Xu and C. Zhong: Circular RNAs in Vascular Functions and Diseases. *Adv Exp Med Biol*, 1087, 287-297 (2018)
DOI: 10.1007/978-981-13-1426-1_23
54. P. B. Pal, H. Sonowal, K. Shukla, S. K. Srivastava and K. V. Ramana: Aldose reductase regulates hyperglycemia-induced HUVEC death via SIRT1/AMPK-alpha1/mTOR pathway. *J Mol Endocrinol* (2019)
DOI: 10.1530/jme-19-0080
55. N. Alexandru, D. Popov and A. Georgescu: Platelet dysfunction in vascular pathologies and how can it be treated. *Thromb Res*, 129(2), 116-26 (2012)
DOI: 10.1016/j.thromres.2011.09.026
56. S. C. Chiu, C. Y. Chao, E. I. Chiang, J. N. Syu, R. L. Rodriguez and F. Y. Tang: N-3 polyunsaturated fatty acids alleviate high glucose-mediated dysfunction of endothelial progenitor cells and prevent ischemic injuries both *in vitro* and *in vivo*. *J Nutr Biochem*, 42, 172-181 (2017)
DOI: 10.1016/j.jnutbio.2017.01.009
57. K. Maiese: Disease onset and aging in the world of circular RNAs. *J Transl Sci*, 2(6), 327-329 (2016)
58. K. Maiese, Z. Z. Chong, Y. C. Shang and J. Hou: Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling? *Expert Opin Ther Targets*, 12(7), 905-16 (2008)
DOI: 10.1517/14728222.12.7.9.05
59. K. Maiese, F. Li, Z. Z. Chong and Y. C. Shang: The Wnt signaling pathway: Aging gracefully as a protectionist? *Pharmacol Ther*, 118(1), 58-81 (2008)
DOI: S0163-7258(08)00017-X
60. N. Perez-Hernandez, G. Vargas-Alarcon, R. Posadas-Sanchez, N. Martinez-Rodriguez, C. A. Tovilla-Zarate, A. A. Rodriguez-Cortes, O. Perez-Mendez, R. Blachman-Braun and J. M. Rodriguez-Perez: PHACTR1 Gene Polymorphism Is Associated with Increased Risk of Developing Premature Coronary Artery Disease in Mexican Population. *Int J Environ Res Public Health*, 13(8) (2016)
DOI: 10.3390/ijerph13080803
61. J. T. Thackeray, J. Radziuk, M. E. Harper, E. J. Suuronen, K. J. Ascah, R. S. Beanlands and J. N. Dasilva: Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia. *Cardiovasc Diabetol*, 10, 75 (2011)
DOI: 10.1186/1475-2840-10-75
62. K. Maiese: Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. *Neural Regen Res*, 10(4), 518-528 (2015)

63. M. Mishra, A. J. Duraisamy and R. A. Kowluru: Sirt1- A Guardian of the Development of Diabetic Retinopathy. *Diabetes* (2018)
DOI: 10.2337/db17-0996
64. M. Ponnalagu, M. Subramani, C. Jayadev, R. Shetty and D. Das: Retinal pigment epithelium-secretome: A diabetic retinopathy perspective. *Cytokine*, 95, 126-135 (2017)
DOI: 10.1016/j.cyto.2017.02.013
65. D. B. Kell and E. Pretorius: No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases. *Biol Rev Camb Philos Soc* (2018)
DOI: 10.1111/brv.12407
66. X. Lin and N. Zhang: Berberine: Pathways to protect neurons. *Phytother Res* (2018)
DOI: 10.1002/ptr.6107
67. K. Maiese: FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus. *Curr Neurovasc Res*, 12(4), 404-413 (2015)
68. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Translating cell survival and cell longevity into treatment strategies with SIRT1. *Rom J Morphol Embryol*, 52(4), 1173-85 (2011)
69. L. Woodhams and H. Al-Salami: The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus. *Ther Deliv*, 8(6), 401-409 (2017)
DOI: 10.4155/tde-2017-0010
70. Y. Zhao, N. A. Scott, S. Fynch, L. Elkerbout, W. W. Wong, K. D. Mason, A. Strasser, D. C. Huang, T. W. Kay and H. E. Thomas: Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes. *Diabetologia*, 58(1), 140-148 (2015)
DOI: 10.1007/s00125-014-3407-5
71. T. Guo, T. Liu, Y. Sun, X. Liu, R. Xiong, H. Li, Z. Li, Z. Zhang, Z. Tian and Y. Tian: Sonodynamic therapy inhibits palmitate-induced beta cell dysfunction via PINK1/Parkin-dependent mitophagy. *Cell Death Dis*, 10(6), 457 (2019)
DOI: 10.1038/s41419-019-1695-x
72. N. Klimova and T. Kristian: Multi-targeted Effect of Nicotinamide Mononucleotide on Brain Bioenergetic Metabolism. *Neurochem Res* (2019)
DOI: 10.1007/s11064-019-02729-0
73. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Novel directions for diabetes mellitus drug discovery. *Expert Opin Drug Discov*, 8(1), 35-48 (2013)
DOI: 10.1517/17460441.2013.736485
74. M. A. M. Othman, E. Rajab, A. AlMubarak, M. AlNaisar, N. Bahzad and A. Kamal: Erythropoietin Protects Against Cognitive Impairment and Hippocampal Neurodegeneration in Diabetic Mice. *Behav Sci (Basel)*, 9(1) (2018)
DOI: 10.3390/bs9010004
75. S. Yelumalai, N. Giribabu, K. Karim, S. Z. Omar and N. B. Salleh: *In vivo* administration of quercetin ameliorates sperm oxidative stress, inflammation, preserves sperm morphology and functions in streptozotocin-nicotinamide induced adult male diabetic rats. *Arch Med Sci*, 15(1), 240-249 (2019)
DOI: 10.5114/aoms.2018.81038

76. S. G. Coca, F. Ismail-Beigi, N. Haq, H. M. Krumholz and C. R. Parikh: Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. *Arch Intern Med*, 172(10), 761-9 (2012)
DOI: 10.1001/archinternmed.2011.2230
77. J. H. Lee, J. H. Lee, M. Jin, S. D. Han, G. R. Chon, I. H. Kim, S. Kim, S. Y. Kim, S. B. Choi and Y. H. Noh: Diet control to achieve euglycemia induces significant loss of heart and liver weight via increased autophagy compared with ad libitum diet in diabetic rats. *Exp Mol Med*, 46, e111 (2014)
DOI: 10.1038/emm.2014.52
78. K. Maiese, Z. Z. Chong, J. Hou and Y. C. Shang: The vitamin nicotinamide: translating nutrition into clinical care. *Molecules*, 14(9), 3446-85 (2009)
DOI: 14093446
79. N. Braidy and Y. Liu: NAD⁺ therapy in age-related degenerative disorders: A benefit/risk analysis. *Exp Gerontol*, 110831 (2020)
DOI: 10.1016/j.exger.2020.110831
80. A. Rex and H. Fink: Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. *Front Biosci*, 13, 3735-41 (2008)
DOI: 2962
81. F. Li, Z. Z. Chong and K. Maiese: Navigating novel mechanisms of cellular plasticity with the NAD⁺ precursor and nutrient nicotinamide. *Front Biosci*, 9, 2500-2520 (2004)
82. K. Maiese and Z. Z. Chong: Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. *Trends Pharmacol Sci*, 24(5), 228-32 (2003)
83. T. M. Jackson, J. M. Rawling, B. D. Roebuck and J. B. Kirkland: Large supplements of nicotinic acid and nicotinamide increase tissue NAD⁺ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. *J Nutr*, 125(6), 1455-61 (1995)
84. M. Wojcik, H. F. Seidle, P. Bieganski and C. Brenner: Glutamine-dependent NAD⁺ synthetase. How a two-domain, three-substrate enzyme avoids waste. *J Biol Chem*, 281(44), 33395-402 (2006)
DOI: M607111200
85. J. A. Khan, F. Forouhar, X. Tao and L. Tong: Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. *Expert Opin Ther Targets*, 11(5), 695-705 (2007)
DOI: 10.1517/14728222.11.5.6.95
86. J. A. Khan, S. Xiang and L. Tong: Crystal structure of human nicotinamide riboside kinase. *Structure*, 15(8), 1005-13 (2007)
DOI: S0969-2126(07)00251-1
87. F. Li, Z. Z. Chong and K. Maiese: Cell Life Versus Cell Longevity: The Mysteries Surrounding the NAD(+) Precursor Nicotinamide. *Curr Med Chem*, 13(8), 883-95 (2006)
88. K. Maiese: Triple play: Promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. *Biomed Pharmacother*, 62(4), 218-232 (2008)
DOI: S0753-3322(08)00026-7
89. G. Magni, A. Amici, M. Emanuelli, G.

- Orsomando, N. Raffaelli and S. Ruggieri: Enzymology of NAD⁺ homeostasis in man. *Cell Mol Life Sci*, 61(1), 19-34 (2004)
90. S. J. Lin and L. Guarente: Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. *Curr Opin Cell Biol*, 15(2), 241-6 (2003)
91. G. J. Hageman and R. H. Stierum: Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. *Mutat Res*, 475(1-2), 45-56 (2001)
92. C. Canto, R. H. Houtkooper, E. Pirinen, D. Y. Youn, M. H. Oosterveer, Y. Cen, P. J. Fernandez-Marcos, H. Yamamoto, P. A. Andreux, P. Cettour-Rose, K. Gademann, C. Rinsch, K. Schoonjans, A. A. Sauve and J. Auwerx: The NAD(+) Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity. *Cell Metab*, 15(6), 838-47 (2012)
DOI: 10.1016/j.cmet.2012.04.022
93. Z. Qi, J. Xia, X. Xue, Q. He, L. Ji and S. Ding: Long-term treatment with nicotinamide induces glucose intolerance and skeletal muscle lipotoxicity in normal chow-fed mice: compared to diet-induced obesity. *J Nutr Biochem*, 36, 31-41 (2016)
DOI: 10.1016/j.jnutbio.2016.07.005
94. D. A. Shear, C. E. Dixon, H. M. Bramlett, S. Mondello, W. D. Dietrich, Y. Deng-Bryant, K. E. Schmid, K. K. Wang, R. L. Hayes, J. T. Povlishock, P. M. Kochanek and F. C. Tortella: Nicotinamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. *J Neurotrauma*, 33(6), 523-37 (2016)
DOI: 10.1089/neu.2015.4115
95. H. N. Jayaram, P. Kusumanchi and J. A. Yalowitz: NMNAT Expression and its Relation to NAD Metabolism. *Curr Med Chem*, 18(13), 1962-72 (2011)
96. Y. Feng, Y. Wang, C. Jiang, Z. Fang, Z. Zhang, X. Lin, L. Sun and W. Jiang: Nicotinamide induces mitochondrial-mediated apoptosis through oxidative stress in human cervical cancer HeLa cells. *Life Sci* (2017)
DOI: 10.1016/j.lfs.2017.06.003
97. C. A. Kulkarni and P. Brookes: Cellular Compartmentation and the Redox/Non-Redox Functions of NAD⁺. *Antioxid Redox Signal* (2019)
DOI: 10.1089/ars.2018.7722
98. E. Turunc Bayrakdar, G. Armagan, Y. Uyanikgil, L. Kanit, E. Koylu and A. Yalcin: Ex vivo protective effects of nicotinamide and 3-aminobenzamide on rat synaptosomes treated with Abeta(1-42). *Cell Biochem Funct* (2014)
DOI: 10.1002/cbf.3049
99. A. C. Williams, L. J. Hill and D. B. Ramsden: Nicotinamide, NAD(P)(H), and Methyl-Group Homeostasis Evolved and Became a Determinant of Ageing Diseases: Hypotheses and Lessons from Pellagra. *Curr Gerontol Geriatr Res*, 2012, 302875 (2012)
DOI: 10.1155/2012/302875
100. M. Yanez, M. Jhanji, K. Murphy, R. M. Gower, M. Sajish and E. Jabbarzadeh: Nicotinamide Augments the Anti-Inflammatory Properties of Resveratrol through PARP1 Activation. *Sci Rep*, 9(1), 10219 (2019)
DOI: 10.1038/s41598-019-46678-8
101. A. Csicsar, S. Tarantini, A. Yabluchanskiy, P. Balasubramanian, T.

- Kiss, E. Farkas, J. A. Baur and Z. I. Ungvari: Role of endothelial NAD⁺ deficiency in age-related vascular dysfunction. *Am J Physiol Heart Circ Physiol* (2019)
DOI: 10.1152/ajpheart.00039.2019
102. C. Lespay-Rebolledo, A. Tapia-Bustos, D. Bustamante, P. Morales and M. Herrera-Marschitz: The Long-Term Impairment in Redox Homeostasis Observed in the Hippocampus of Rats Subjected to Global Perinatal Asphyxia (PA) Implies Changes in Glutathione-Dependent Antioxidant Enzymes and TIGAR-Dependent Shift Towards the Pentose Phosphate Pathways: Effect of Nicotinamide. *Neurotox Res* (2019)
DOI: 10.1007/s12640-019-00064-4
103. A. Ieraci and D. G. Herrera: Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum. *Cerebellum* (2018)
DOI: 10.1007/s12311-017-0916-z
104. Z. Z. Chong, S. H. Lin and K. Maiese: The NAD⁺ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. *J Cereb Blood Flow Metab*, 24(7), 728-43 (2004)
105. K. Maiese: The bright side of reactive oxygen species: lifespan extension without cellular demise. *J Transl Sci*, 2(3), 185-187 (2016)
DOI: 10.15761/jts.1000138
106. Z. Z. Chong, F. Li and K. Maiese: Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. *Prog Neurobiol*, 75(3), 207-46 (2005)
107. N. Karamzad, V. Maleki, K. Carson-Chahhoud, S. Azizi, A. Sahebkar and B. P. Gargari: A systematic review on the mechanisms of vitamin K effects on the complications of diabetes and pre-diabetes. *Biofactors* (2019)
DOI: 10.1002/biof.1569
108. Y. I. Mahmoud and A. A. Mahmoud: Role of nicotinamide (vitamin B3) in acetaminophen-induced changes in rat liver: Nicotinamide effect in acetaminophen-damaged liver. *Exp Toxicol Pathol* (2016)
DOI: 10.1016/j.etp.2016.05.003
109. J. Wang, P. Sun, Y. Bao, B. Dou, D. Song and Y. Li: Vitamin E renders protection to PC12 cells against oxidative damage and apoptosis induced by single-walled carbon nanotubes. *Toxicol In vitro*, 26(1), 32-41 (2012)
DOI: 10.1016/j.tiv.2011.10.004
110. J. Wohlrab and D. Kreft: Niacinamide - mechanisms of action and its topical use in dermatology. *Skin Pharmacol Physiol*, 27(6), 311-5 (2014)
DOI: 10.1159/000359974
111. P. Xu and A. A. Sauve: Vitamin B3, the nicotinamide adenine dinucleotides and aging. *Mech Ageing Dev*, 131(4), 287-98 (2010)
DOI: 10.1016/j.mad.2010.03.006
112. H. Yuan, J. Wan, L. Li, P. Ge, H. Li and L. Zhang: Therapeutic benefits of the group B3 vitamin nicotinamide in mice with lethal endotoxemia and polymicrobial sepsis. *Pharmacol Res*, 65(3), 328-37 (2012)
DOI: 10.1016/j.phrs.2011.11.014
113. C. Zhou, L. Na, R. Shan, Y. Cheng, Y. Li, X. Wu and C. Sun: Dietary Vitamin C

- Intake Reduces the Risk of Type 2 Diabetes in Chinese Adults: HOMA-IR and T-AOC as Potential Mediators. *PLoS One*, 11(9), e0163571 (2016)
DOI: 10.1371/journal.pone.0163571
114. R. Castro-Portuguez and G. L. Sutphin: Kynurenine pathway, NAD(+) synthesis, and mitochondrial function: Targeting tryptophan metabolism to promote longevity and healthspan. *Exp Gerontol*, 110841 (2020)
DOI: 10.1016/j.exger.2020.110841
115. Z. Z. Chong, F. Li and K. Maiese: Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. *Brain Res Brain Res Rev*, 49(1), 1-21 (2005)
116. V. Balan, G. S. Miller, L. Kaplun, K. Balan, Z. Z. Chong, F. Li, A. Kaplun, M. F. VanBerkum, R. Arking, D. C. Freeman, K. Maiese and G. Tzivion: Life span extension and neuronal cell protection by *Drosophila* nicotinamidase. *J Biol Chem*, 283(41), 27810-9 (2008)
DOI: M804681200
117. Z. Z. Chong and K. Maiese: Enhanced Tolerance against Early and Late Apoptotic Oxidative Stress in Mammalian Neurons through Nicotinamidase and Sirtuin Mediated Pathways. *Curr Neurovasc Res*, 5(3), 159-70 (2008)
118. T. C. Peterson, M. R. Hoane, K. McConomy, F. Farin, T. Bammler, J. MacDonald, E. Kantor and G. Anderson: A Combination Therapy of Nicotinamide and Progesterone Improves Functional Recovery Following Traumatic Brain Injury. *J Neurotrauma* (2014)
DOI: 10.1089/neu.2014.3530
119. Y. Zhang, J. Wang, G. Chen, D. Fan and M. Deng: Inhibition of Sirt1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells. *Biochem Biophys Res Commun*, 404(2), 610-4 (2011)
DOI: 10.1016/j.bbrc.2010.12.014
120. B. Poljsak and I. Milisav: The NAD(+)-depletion theory of ageing: NAD(+) as the link between oxidative stress, inflammation, caloric restriction, exercise, DNA repair, longevity and health span. *Rejuvenation Res* (2016)
DOI: 10.1089/rej.2015.1767
121. Z. Z. Chong, S. H. Lin and K. Maiese: Nicotinamide Modulates Mitochondrial Membrane Potential and Cysteine Protease Activity during Cerebral Vascular Endothelial Cell Injury. *J Vasc Res*, 39(2), 131-47. (2002)
122. O. Itzhaki, E. Greenberg, B. Shalmon, A. Kubi, A. J. Treves, R. Shapira-Frommer, C. Avivi, R. Ortenberg, E. Ben-Ami, J. Schachter, M. J. Besser and G. Markel: Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. *PLoS One*, 8(2), e57160 (2013)
DOI: 10.1371/journal.pone.0057160
123. Y. Mikhed, A. Daiber and S. Steven: Mitochondrial Oxidative Stress, Mitochondrial DNA Damage and Their Role in Age-Related Vascular Dysfunction. *Int J Mol Sci*, 16(7), 15918-15953 (2015)
DOI: 10.3390/ijms160715918
124. E. Turunc Bayrakdar, Y. Uyanikgil, L. Kanit, E. Koylu and A. Yalcin: Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in Abeta(1-42)-induced rat model of Alzheimer's disease. *Free*

- Radix Res*, 48(2), 146-58 (2014)
DOI: 10.3109/10715762.2013.857018
125. K. Kiuchi, K. Yoshizawa, N. Shikata, M. Matsumura and A. Tsubura: Nicotinamide prevents N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in Sprague-Dawley rats and C57BL mice. *Exp Eye Res*, 74(3), 383-92 (2002)
126. S. H. Lin, A. Vincent, T. Shaw, K. I. Maynard and K. Maiese: Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. *J Cereb Blood Flow Metab*, 20(9), 1380-91 (2000)
127. L. Naia, T. R. Rosenstock, A. M. Oliveira, S. I. Oliveira-Sousa, G. L. Caldeira, C. Carmo, M. N. Laco, M. R. Hayden, C. R. Oliveira and A. C. Rego: Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models. *Mol Neurobiol* (2016)
DOI: 10.1007/s12035-016-0048-3
128. A. Ahangarpour, F. Ramezani Ali Akbari and H. Fathi Moghadam: Effect of C-peptide Alone or in Combination with Nicotinamide on Glucose and Insulin Levels in Streptozotocin-Nicotinamide-Induced Type 2 Diabetic Mice. *Malays J Med Sci*, 21(4), 12-7 (2014)
129. J. Folwarczna, A. Janas, U. Cegiela, M. Pytlik, L. Sliwinski, M. Matejczyk, A. Nowacka, K. Rudy, Z. Krivosikova, K. Stefikova and M. Gajdos: Caffeine at a Moderate Dose Did Not Affect the Skeletal System of Rats with Streptozotocin-Induced Diabetes. *Nutrients*, 9(11) (2017)
DOI: 10.3390/nu9111196
130. A. Ghasemi, S. Khalifi and S. Jedi: Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (review). *Acta Physiol Hung*, 101(4), 408-20 (2014)
DOI: 10.1556/APhysiol.101.2014.4.2
131. S. Guo, Q. Chen, Y. Sun and J. Chen: Nicotinamide protects against skeletal muscle atrophy in streptozotocin-induced diabetic mice. *Arch Physiol Biochem*, 125(5), 470-477 (2019)
DOI: 10.1080/13813455.2019.1638414
132. H. J. Lee and S. J. Yang: Supplementation with Nicotinamide Riboside Reduces Brain Inflammation and Improves Cognitive Function in Diabetic Mice. *Int J Mol Sci*, 20(17) (2019)
DOI: 10.3390/ijms20174196
133. S. Reddy, N. J. Bibby, D. Wu, C. Swinney, G. Barrow and R. B. Elliott: A combined casein-free-nicotinamide diet prevents diabetes in the NOD mouse with minimum insulinitis. *Diabetes Res Clin Pract*, 29(2), 83-92 (1995)
134. Y. Hu, Y. Wang, L. Wang, H. Zhang, B. Zhao, A. Zhang and Y. Li: Effects of nicotinamide on prevention and treatment of streptozotocin-induced diabetes mellitus in rats. *Chin Med J (Engl)*, 109(11), 819-22 (1996)
135. S. Chlopicki, J. Swies, A. Mogielnicki, W. Buczek, M. Bartus, M. Lomnicka, J. Adamus and J. Gebicki: 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. *Br J Pharmacol*, 152(2), 230-9 (2007)
136. Z. Z. Chong, S. H. Lin, F. Li and K. Maiese: The sirtuin inhibitor nicotinamide

- enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP, and mitochondrial associated "anti-apoptotic" pathways. *Curr Neurovasc Res*, 2(4), 271-85 (2005)
137. N. Hara, K. Yamada, T. Shibata, H. Osago, T. Hashimoto and M. Tsuchiya: Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. *J Biol Chem*, 282(34), 24574-82 (2007)
 138. A. Ieraci and D. G. Herrera: Nicotinamide Protects against Ethanol-Induced Apoptotic Neurodegeneration in the Developing Mouse Brain. *PLoS Med*, 3(4), e101 (2006)
 139. D. Tam, M. Tam and K. I. Maynard: Nicotinamide modulates energy utilization and improves functional recovery from ischemia in the *in vitro* rabbit retina. *Ann N Y Acad Sci*, 1053, 258-68 (2005)
 140. P. R. Olmos, M. I. Hodgson, A. Maiz, M. Manrique, M. D. De Valdes, R. Foncea, A. M. Acosta, M. V. Emmerich, S. Velasco, O. P. Muniz, C. A. Oyarzun, J. C. Claro, M. J. Bastias and L. A. Toro: Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. *Diabetes Res Clin Pract*, 71(3), 320-33 (2006)
DOI: S0168-8227(05)00328-1
 141. A. Crino, R. Schiaffini, P. Ciampalini, M. C. Suraci, S. Manfrini, N. Visalli, M. C. Matteoli, P. Patera, R. Buzzetti, C. Guglielmi, S. Spera, F. Costanza, E. Fioriti, D. Pitocco and P. Pozzilli: A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*, 18(8), 749-54 (2005)
 142. H. K. Liu, B. D. Green, P. R. Flatt, N. H. McClenaghan and J. T. McCluskey: Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells. *Endocr Res*, 30(1), 61-8 (2004)
 143. S. Reddy, N. Salari-Lak and S. Sandler: Long-term effects of nicotinamide-induced inhibition of poly(adenosine diphosphate-ribose) polymerase activity in rat pancreatic islets exposed to interleukin-1 beta. *Endocrinology*, 136(5), 1907-12 (1995)
 144. C. Gaudineau and K. Auclair: Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. *Biochem Biophys Res Commun*, 317(3), 950-6 (2004)
 145. A. F. Schinder, E. C. Olson, N. C. Spitzer and M. Montal: Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. *J Neurosci*, 16(19), 6125-33. (1996)
 146. D. H. Walter, J. Haendeler, J. Galle, A. M. Zeiher and S. Dimmeler: Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. *Circulation*, 98(12), 1153-7. (1998)
 147. A. P. Halestrap, K. Y. Woodfield and C. P. Connern: Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. *J Biol Chem*, 272(6), 3346-54 (1997)

148. G. La Piana, D. Marzulli, M. I. Consalvo and N. E. Lofrumento: Cytochrome c-induced cytosolic nicotinamide adenine dinucleotide oxidation, mitochondrial permeability transition, and apoptosis. *Arch Biochem Biophys*, 410(2), 201-11 (2003)
149. D. J. Klionsky, K. Abdelmohsen, A. Abe, M. J. Abedin, H. Abeliovich, A. Acevedo Arozena, H. Adachi, C. M. Adams, P. D. Adams, K. Adeli, P. J. Adhihetty, S. G. Adler, G. Agam, R. Agarwal, M. K. Aghi, M. Agnello, P. Agostinis, P. V. Aguilar, J. Aguirre-Ghiso, E. M. Airoidi, S. Ait-Si-Ali, T. Akematsu, E. T. Akporiaye, M. Al-Rubeai, G. M. Albaiceta, C. Albanese, D. Albani, M. L. Albert, J. Aldudo, H. Algul, M. Alirezaei, I. Alloza, A. Almasan, M. Almonte-Beceril, E. S. Alnemri, C. Alonso, N. Altan-Bonnet, D. C. Altieri, S. Alvarez, L. Alvarez-Erviti, S. Alves, G. Amadoro, A. Amano, C. Amantini, S. Ambrosio, I. Amelio, A. O. Amer, M. Amessou, A. Amon, Z. An, F. A. Anania, S. U. Andersen, U. P. Andley, C. K. Andreadi, N. Andrieu-Abadie, A. Anel, D. K. Ann, S. Anoopkumar-Dukie, M. Antonioli, H. Aoki, N. Apostolova, S. Aquila, K. Aquilano, K. Araki, E. Arama, A. Aranda, J. Araya, A. Arcaro, E. Arias, H. Arimoto, A. R. Ariosa, J. L. Armstrong, T. Arnould, I. Arsov, K. Asanuma, V. Askanas, E. Asselin, R. Atarashi, S. S. Atherton, J. D. Atkin, L. D. Attardi, P. Auburger, G. Auburger, L. Aurelian, R. Autelli, L. Avagliano, M. L. Avantaggiati, L. Avrahami, S. Awale, N. Azad, T. Bachetti, J. M. Backer, D. H. Bae, J. S. Bae, O. N. Bae, S. H. Bae, E. H. Baehrecke, S. H. Baek, S. Baghdiguian, A. Bagniewska-Zadworna, H. Bai, J. Bai, X. Y. Bai, Y. Bailly, K. N. Balaji, W. Balduini, A. Ballabio, R. Balzan, R. Banerjee, G. Banhegyi, H. Bao, B. Barbeau, M. D. Barrachina, E. Barreiro, B. Bartel, A. Bartolome, D. C. Bassham, M. T. Bassi, R. C. Bast, Jr., A. Basu, M. T. Batista, H. Batoko, M. Battino, K. Bauckman, B. L. Baumgarner, K. U. Bayer, R. Beale, J. F. Beaulieu, G. R. Beck, Jr., C. Becker, J. D. Beckham, P. A. Bedard, P. J. Bednarski, T. J. Begley, C. Behl, C. Behrends, G. M. Behrens, K. E. Behrns, E. Bejarano, A. Belaid, F. Belleudi, G. Benard, G. Berchem, D. Bergamaschi, M. Bergami, B. Berkhout, L. Berliocchi, A. Bernard, M. Bernard, F. Bernassola, A. Bertolotti, A. S. Bess, S. Besteiro, S. Bettuzzi, S. Bhalla, S. Bhattacharyya, S. K. Bhutia, C. Biagosch, M. W. Bianchi, M. Biard-Piechaczyk, V. Billes, C. Bincoletto, B. Bingol, S. W. Bird, M. Bitoun, I. Bjedov, C. Blackstone, L. Blanc, G. A. Blanco, H. K. Blomhoff, E. Boada-Romero, S. Bockler, M. Boes, K. Boesze-Battaglia, L. H. Boise, A. Bolino, A. Boman, P. Bonaldo, M. Bordi, J. Bosch, L. M. Botana, J. Botti, G. Bou, M. Bouche, M. Bouhecareilh, M. J. Boucher, M. E. Boulton, S. G. Bouret, P. Boya, M. Boyer-Guittaut, P. V. Bozhkov, N. Brady, V. M. Braga, C. Brancolini, G. H. Braus, J. M. Bravo-San Pedro, L. A. Brennan, E. H. Bresnick, P. Brest, D. Bridges, M. A. Bringer, M. Brini, G. C. Brito, B. Brodin, P. S. Brookes, E. J. Brown, K. Brown, H. E. Broxmeyer, A. Bruhat, P. C. Brum, J. H. Brumell, N. Brunetti-Pierri, R. J. Bryson-Richardson, S. Buch, A. M. Buchan, H. Budak, D. V. Bulavin, S. J. Bultman, G. Bultynck, V. Bumbasirevic, Y. Burelle, R. E. Burke, M. Burmeister, P. Butikofer, L. Caberlotto, K. Cadwell, M. Cahova, D. Cai, J. Cai, Q. Cai, S. Calatayud, N. Camougrand, M. Campanella, G. R. Campbell, M. Campbell, S. Campello, R. Candau, I. Caniggia, L. Cantoni, L. Cao, A. B. Caplan, M. Caraglia, C. Cardinali, S. M.

- Cardoso, J. S. Carew, L. A. Carleton, C. R. Carlin, S. Carloni, S. R. Carlsson, D. Carmona-Gutierrez, L. A. Carneiro, O. Carnevali, S. Carra, A. Carrier, B. Carroll, C. Casas, J. Casas, G. Cassinelli, P. Castets, S. Castro-Obregon, G. Cavallini, I. Ceccherini, F. Cecconi, A. I. Cederbaum, V. Cena, S. Cenci, C. Cerella, D. Cervia, S. Cetrullo, H. Chaachouay, H. J. Chae, A. S. Chagin, C. Y. Chai, G. Chakrabarti, G. Chamilos, E. Y. Chan, M. T. Chan, D. Chandra, P. Chandra, C. P. Chang, R. C. Chang, T. Y. Chang, J. C. Chatham, S. Chatterjee, S. Chauhan, Y. Che, M. E. Cheetham, R. Cheluvappa, C. J. Chen, G. Chen, G. C. Chen, G. Chen, H. Chen, J. W. Chen, J. K. Chen, M. Chen, M. Chen, P. Chen, Q. Chen, Q. Chen, S. D. Chen, S. Chen, S. S. Chen, W. Chen, W. J. Chen, W. Q. Chen, W. Chen, X. Chen, Y. H. Chen, Y. G. Chen, Y. Chen, Y. Chen, Y. Chen, Y. J. Chen, Y. Q. Chen, Y. Chen, Z. Chen, Z. Chen, A. Cheng, C. H. Cheng, H. Cheng, H. Cheong, S. Cherry, J. Chesney, C. H. Cheung, E. Chevet, H. C. Chi, S. G. Chi, F. Chiacchiera, H. L. Chiang, R. Chiarelli, M. Chiariello, M. Chieppa, L. S. Chin, M. Chiong, G. N. Chiu, D. H. Cho, S. G. Cho, W. C. Cho, Y. Y. Cho, Y. S. Cho, A. M. Choi, E. J. Choi, E. K. Choi, J. Choi, M. E. Choi, S. I. Choi, T. F. Chou, S. Chouaib, D. Choubey, V. Choubey, K. C. Chow, K. Chowdhury, C. T. Chu, T. H. Chuang, T. Chun, H. Chung, T. Chung, Y. L. Chung, Y. J. Chwae, V. Cianfanelli, R. Ciarcia, I. A. Ciechomska, M. R. Ciriolo, M. Cirone, S. Claerhout, M. J. Clague, J. Claria, P. G. Clarke, R. Clarke, E. Clementi, C. Cleyrat, M. Cnop, E. M. Coccia, T. Cocco, P. Codogno, J. Coers, E. E. Cohen, D. Colecchia, L. Coletto, N. S. Coll, E. Colucci-Guyon, S. Comincini, M. Condello, K. L. Cook, G. H. Coombs, C. D. Cooper, J. M. Cooper, I. Coppens, M. T. Corasaniti, M. Corazzari, R. Corbalan, E. Corcelle-Termeau, M. D. Cordero, C. Corral-Ramos, O. Corti, A. Cossarizza, P. Costelli, S. Costes, S. L. Cotman, A. Coto-Montes, S. Cottet, E. Couve, L. R. Covey, L. A. Cowart, J. S. Cox, F. P. Coxon, C. B. Coyne, M. S. Cragg, R. J. Craven, T. Crepaldi, J. L. Crespo, A. Criollo, V. Crippa, M. T. Cruz, A. M. Cuervo, J. M. Cuezva, T. Cui, P. R. Cutillas, M. J. Czaja, M. F. Czyzyk-Krzeska, R. K. Dagda, U. Dahmen, C. Dai, W. Dai, Y. Dai, K. N. Dalby, L. Dalla Valle, G. Dalmasso, M. D'Amelio, M. Damme, A. Darfeuille-Michaud, C. Dargemont, V. M. Darley-Usmar, S. Dasarathy, B. Dasgupta, S. Dash, C. R. Dass, H. M. Davey, L. M. Davids, D. Davila, R. J. Davis, T. M. Dawson, V. L. Dawson, P. Daza, J. de Belleruche, P. de Figueiredo, R. C. de Figueiredo, J. de la Fuente, L. De Martino, A. De Matteis, G. R. De Meyer, A. De Milito, M. De Santi, W. de Souza, V. De Tata, D. De Zio, J. Debnath, R. Dechant, J. P. Decuyper, S. Deegan, B. Dehay, B. Del Bello, D. P. Del Re, R. Delage-Mourroux, L. M. Delbridge, L. Deldicque, E. Delorme-Axford, Y. Deng, J. Dengjel, M. Denizot, P. Dent, C. J. Der, V. Deretic, B. Derrien, E. Deutsch, T. P. Devarenne, R. J. Devenish, S. Di Bartolomeo, N. Di Daniele, F. Di Domenico, A. Di Nardo, S. Di Paola, A. Di Pietro, L. Di Renzo, A. DiAntonio, G. Diaz-Araya, I. Diaz-Laviada, M. T. Diaz-Meco, J. Diaz-Nido, C. A. Dickey, R. C. Dickson, M. Diederich, P. Digard, I. Dikic, S. P. Dinesh-Kumar, C. Ding, W. X. Ding, Z. Ding, L. Dini, J. H. Distler, A. Diwan, M. Djavaheri-Mergny, K. Dmytruk, R. C. Dobson, V. Doetsch, K. Dokladny, S. Dokudovskaya, M. Donadelli, X. C. Dong, X. Dong, Z. Dong, T. M. Donohue, Jr., K. S. Doran, G. D'Orazi, G. W. Dorn, 2nd, V.

- Dosenko, S. Dridi, L. Drucker, J. Du, L. L. Du, L. Du, A. du Toit, P. Dua, L. Duan, P. Duann, V. K. Dubey, M. R. Duchen, M. A. Duchosal, H. Duez, I. Dugail, V. I. Dumit, M. C. Duncan, E. A. Dunlop, W. A. Dunn, Jr., N. Dupont, L. Dupuis, R. V. Duran, T. M. Durcan, S. Duvezin-Caubet, U. Duvvuri, V. Eapen, D. Ebrahimi-Fakhari, A. Echard, L. Eckhart, C. L. Edelstein, A. L. Edinger, L. Eichinger, T. Eisenberg, A. Eisenberg-Lerner, N. T. Eissa, W. S. El-Deiry, V. El-Khoury, Z. Elazar, H. Eldar-Finkelman, C. J. Elliott, E. Emanuele, U. Emmenegger, N. Engedal, A. M. Engelbrecht, S. Engelder, J. M. Enserink, R. Erdmann, J. Erenpreisa, R. Eri, J. L. Eriksen, A. Erman, R. Escalante, E. L. Eskelinen, L. Espert, L. Esteban-Martinez, T. J. Evans, M. Fabri, G. Fabrias, C. Fabrizi, A. Facchiano, N. J. Faergeman, A. Faggioni, W. D. Fairlie, C. Fan, D. Fan, J. Fan, S. Fang, M. Fanto, A. Fanzani, T. Farkas, M. Faure, F. B. Favier, H. Fearnhead, M. Federici, E. Fei, T. C. Felizardo, H. Feng, Y. Feng, Y. Feng, T. A. Ferguson, A. F. Fernandez, M. G. Fernandez-Barrena, J. C. Fernandez-Checa, A. Fernandez-Lopez, M. E. Fernandez-Zapico, O. Feron, E. Ferraro, C. V. Ferreira-Halder, L. Fesus, R. Feuer, F. C. Fiesel, E. C. Filippi-Chiela, G. Filomeni, G. M. Fimia, J. H. Fingert, S. Finkbeiner, T. Finkel, F. Fiorito, P. B. Fisher, M. Flajolet, F. Flamigni, O. Florey, S. Florio, R. A. Floto, M. Folini, C. Follo, E. A. Fon, F. Fornai, F. Fortunato, A. Fraldi, R. Franco, A. Francois, A. Francois, L. B. Frankel, I. D. Fraser, N. Frey, D. G. Freyssenet, C. Frezza, S. L. Friedman, D. E. Frigo, D. Fu, J. M. Fuentes, J. Fueyo, Y. Fujitani, Y. Fujiwara, M. Fujiya, M. Fukuda, S. Fulda, C. Fusco, B. Gabryel, M. Gaestel, P. Gailly, M. Gajewska, S. Galadari, G. Galili, I. Galindo, M. F. Galindo, G. Galliciotti, L. Galluzzi, L. Galluzzi, V. Galy, N. Gammoh, S. Gandy, A. K. Ganesan, S. Ganesan, I. G. Ganley, M. Gannage, F. B. Gao, F. Gao, J. X. Gao, L. Garcia Nannig, E. Garcia Vescovi, M. Garcia-Macia, C. Garcia-Ruiz, A. D. Garg, P. K. Garg, R. Gargini, N. C. Gassen, D. Gatica, E. Gatti, J. Gavard, E. Gavathiotis, L. Ge, P. Ge, S. Ge, P. W. Gean, V. Gelmetti, A. A. Genazzani, J. Geng, P. Genschik, L. Gerner, J. E. Gestwicki, D. A. Gewirtz, S. Ghavami, E. Ghigo, D. Ghosh, A. M. Giammarioli, F. Giampieri, C. Giampietri, A. Giatromanolaki, D. J. Gibbins, L. Gibellini, S. B. Gibson, V. Ginot, A. Giordano, F. Giorgini, E. Giovannetti, S. E. Girardin, S. Gispert, S. Giuliano, C. L. Gladson, A. Glavic, M. Gleave, N. Godefroy, R. M. Gogal, Jr., K. Gokulan, G. H. Goldman, D. Goletti, M. S. Goligorsky, A. V. Gomes, L. C. Gomes, H. Gomez, C. Gomez-Manzano, R. Gomez-Sanchez, D. A. Goncalves, E. Goncu, Q. Gong, C. Gongora, C. B. Gonzalez, P. Gonzalez-Alegre, P. Gonzalez-Cabo, R. A. Gonzalez-Polo, I. S. Goping, C. Gorbea, N. V. Gorbunov, D. R. Goring, A. M. Gorman, S. M. Gorski, S. Goruppi, S. Goto-Yamada, C. Gotor, R. A. Gottlieb, I. Gozes, D. Gozuacik, Y. Graba, M. Graef, G. E. Granato, G. D. Grant, S. Grant, G. L. Gravina, D. R. Green, A. Greenhough, M. T. Greenwood, B. Grimaldi, F. Gros, C. Grose, J. F. Groulx, F. Gruber, P. Grumati, T. Grune, J. L. Guan, K. L. Guan, B. Guerra, C. Guillen, K. Gulshan, J. Gunst, C. Guo, L. Guo, M. Guo, W. Guo, X. G. Guo, A. A. Gust, A. B. Gustafsson, E. Gutierrez, M. G. Gutierrez, H. S. Gwak, A. Haas, J. E. Haber, S. Hadano, M. Hagedorn, D. R. Hahn, A. J. Halayko, A. Hamacher-Brady, K. Hamada, A. Hamai, A. Hamann, M.

- Hamasaki, I. Hamer, Q. Hamid, E. M. Hammond, F. Han, W. Han, J. T. Handa, J. A. Hanover, M. Hansen, M. Harada, L. Harhaji-Trajkovic, J. W. Harper, A. H. Harrath, A. L. Harris, J. Harris, U. Hasler, P. Hasselblatt, K. Hasui, R. G. Hawley, T. S. Hawley, C. He, C. Y. He, F. He, G. He, R. R. He, X. H. He, Y. W. He, Y. Y. He, J. K. Heath, M. J. Hebert, R. A. Heinzen, G. V. Helgason, M. Hensel, E. P. Henske, C. Her, P. K. Herman, A. Hernandez, C. Hernandez, S. Hernandez-Tiedra, C. Hetz, P. R. Hiesinger, K. Higaki, S. Hilfiker, B. G. Hill, J. A. Hill, W. D. Hill, K. Hino, D. Hofius, P. Hofman, G. U. Hoglinger, J. Hohfeld, M. K. Holz, Y. Hong, D. A. Hood, J. J. Hoozemans, T. Hoppe, C. Hsu, C. Y. Hsu, L. C. Hsu, D. Hu, G. Hu, H. M. Hu, H. Hu, M. C. Hu, Y. C. Hu, Z. W. Hu, F. Hua, Y. Hua, C. Huang, H. L. Huang, K. H. Huang, K. Y. Huang, S. Huang, S. Huang, W. P. Huang, Y. R. Huang, Y. Huang, Y. Huang, T. B. Huber, P. Huebbe, W. K. Huh, J. J. Hulmi, G. M. Hur, J. H. Hurley, Z. Husak, S. N. Hussain, S. Hussain, J. J. Hwang, S. Hwang, T. I. Hwang, A. Ichihara, Y. Imai, C. Imbriano, M. Inomata, T. Into, V. Iovane, J. L. Iovanna, R. V. Iozzo, N. Y. Ip, J. E. Irazoqui, P. Iribarren, Y. Isaka, A. J. Isakovic, H. Ischiropoulos, J. S. Isenberg, M. Ishaq, H. Ishida, I. Ishii, J. E. Ishmael, C. Isidoro, K. I. Isobe, E. Isono, S. Issazadeh-Navikas, K. Itahana, E. Itakura, A. I. Ivanov, A. K. Iyer, J. M. Izquierdo, Y. Izumi, V. Izzo, M. Jaattela, N. Jaber, D. J. Jackson, W. T. Jackson, T. G. Jacob, T. S. Jacques, C. Jagannath, A. Jain, N. R. Jana, B. K. Jang, A. Jani, B. Janji, P. R. Jannig, P. J. Jansson, S. Jean, M. Jendrach, J. H. Jeon, N. Jessen, E. B. Jeung, K. Jia, L. Jia, H. Jiang, H. Jiang, L. Jiang, T. Jiang, X. Jiang, X. Jiang, X. Jiang, Y. Jiang, Y. Jiang, A. Jimenez, C. Jin, H. Jin, L. Jin, M. Jin, S. Jin, U. K. Jinwal, E. K. Jo, T. Johansen, D. E. Johnson, G. V. Johnson, J. D. Johnson, E. Jonasch, C. Jones, L. A. Joosten, J. Jordan, A. M. Joseph, B. Joseph, A. M. Joubert, D. Ju, J. Ju, H. F. Juan, K. Juenemann, G. Juhasz, H. S. Jung, J. U. Jung, Y. K. Jung, H. Jungbluth, M. J. Justice, B. Jutten, N. O. Kaakoush, K. Kaarniranta, A. Kaasik, T. Kabuta, B. Kaeffer, K. Kagedal, A. Kahana, S. Kajimura, O. Kakhlon, M. Kalia, D. V. Kalvakolanu, Y. Kamada, K. Kambas, V. O. Kaminsky, H. H. Kampinga, M. Kandouz, C. Kang, R. Kang, T. C. Kang, T. Kanki, T. D. Kanneganti, H. Kanno, A. G. Kanthasamy, M. Kantorow, M. Kaparakis-Liaskos, O. Kapuy, V. Karantza, M. R. Karim, P. Karmakar, A. Kaser, S. Kaushik, T. Kawula, A. M. Kaynar, P. Y. Ke, Z. J. Ke, J. H. Kehrl, K. E. Keller, J. K. Kemper, A. K. Kenworthy, O. Kepp, A. Kern, S. Kesari, D. Kessel, R. Ketteler, I. D. Kettelhut, B. Khambu, M. M. Khan, V. K. Khandelwal, S. Khare, J. G. Kiang, A. A. Kiger, A. Kihara, A. L. Kim, C. H. Kim, D. R. Kim, D. H. Kim, E. K. Kim, H. Y. Kim, H. R. Kim, J. S. Kim, J. H. Kim, J. C. Kim, J. H. Kim, K. W. Kim, M. D. Kim, M. M. Kim, P. K. Kim, S. W. Kim, S. Y. Kim, Y. S. Kim, Y. Kim, A. Kimchi, A. C. Kimmelman, T. Kimura, J. S. King, K. Kirkegaard, V. Kirkin, L. A. Kirshenbaum, S. Kishi, Y. Kitajima, K. Kitamoto, Y. Kitaoka, K. Kitazato, R. A. Kley, W. T. Klimecki, M. Klinkenberg, J. Klucken, H. Knaevelsrud, E. Knecht, L. Knuppertz, J. L. Ko, S. Kobayashi, J. C. Koch, C. Koechlin-Ramonatxo, U. Koenig, Y. H. Koh, K. Kohler, S. D. Kohlwein, M. Koike, M. Komatsu, E. Kominami, D. Kong, H. J. Kong, E. G. Konstantakou, B. T. Kopp, T. Korcsmaros, L. Korhonen, V. I. Korolchuk, N. V. Koshkina, Y. Kou, M. I.

- Koukourakis, C. Koumenis, A. L. Kovacs, T. Kovacs, W. J. Kovacs, D. Koya, C. Kraft, D. Krainc, H. Kramer, T. Kravic-Stevovic, W. Krek, C. Kretz-Remy, R. Krick, M. Krishnamurthy, J. Kriston-Vizi, G. Kroemer, M. C. Kruer, R. Kruger, N. T. Ktistakis, K. Kuchitsu, C. Kuhn, A. P. Kumar, A. Kumar, A. Kumar, D. Kumar, D. Kumar, R. Kumar, S. Kumar, M. Kundu, H. J. Kung, A. Kuno, S. H. Kuo, J. Kuret, T. Kurz, T. Kwok, T. K. Kwon, Y. T. Kwon, I. Kyrmizi, A. R. La Spada, F. Lafont, T. Lahm, A. Lakkaraju, T. Lam, T. Lamark, S. Lancel, T. H. Landowski, D. J. Lane, J. D. Lane, C. Lanzi, P. Lapaquette, L. R. Lapierre, J. Laporte, J. Laukkarinen, G. W. Laurie, S. Lavandero, L. Lavie, M. J. LaVoie, B. Y. Law, H. K. Law, K. B. Law, R. Layfield, P. A. Lazo, L. Le Cam, K. G. Le Roch, H. Le Stunff, V. Leardkamolkarn, M. Lecuit, B. H. Lee, C. H. Lee, E. F. Lee, G. M. Lee, H. J. Lee, H. Lee, J. K. Lee, J. Lee, J. H. Lee, J. H. Lee, M. Lee, M. S. Lee, P. J. Lee, S. W. Lee, S. J. Lee, S. J. Lee, S. Y. Lee, S. H. Lee, S. S. Lee, S. J. Lee, S. Lee, Y. R. Lee, Y. J. Lee, Y. H. Lee, C. Leeuwenburgh, S. Lefort, R. Legouis, J. Lei, Q. Y. Lei, D. A. Leib, G. Leibowitz, I. Lekli, S. D. Lemaire, J. J. Lemasters, M. K. Lemberg, A. Lemoine, S. Leng, G. Lenz, P. Lenzi, L. O. Lerman, D. Lettieri Barbato, J. I. Leu, H. Y. Leung, B. Levine, P. A. Lewis, F. Lezoualc'h, C. Li, F. Li, F. J. Li, J. Li, K. Li, L. Li, M. Li, M. Li, Q. Li, R. Li, S. Li, W. Li, W. Li, X. Li, Y. Li, J. Lian, C. Liang, Q. Liang, Y. Liao, J. Liberal, P. P. Liberski, P. Lie, A. P. Lieberman, H. J. Lim, K. L. Lim, K. Lim, R. T. Lima, C. S. Lin, C. F. Lin, F. Lin, F. Lin, F. C. Lin, K. Lin, K. H. Lin, P. H. Lin, T. Lin, W. W. Lin, Y. S. Lin, Y. Lin, R. Linden, D. Lindholm, L. M. Lindqvist, P. Lingor, A. Linkermann, L. A. Liotta, M. M. Lipinski, V. A. Lira, M. P. Lisanti, P. B. Liton, B. Liu, C. Liu, C. F. Liu, F. Liu, H. J. Liu, J. Liu, J. J. Liu, J. L. Liu, K. Liu, L. Liu, L. Liu, Q. Liu, R. Y. Liu, S. Liu, S. Liu, W. Liu, X. D. Liu, X. Liu, X. H. Liu, X. Liu, X. Liu, X. Liu, Y. Liu, Y. Liu, Z. Liu, Z. Liu, J. P. Liuzzi, G. Lizard, M. Ljubic, I. J. Lodhi, S. E. Logue, B. L. Lokeshwar, Y. C. Long, S. Lonial, B. Loos, C. Lopez-Otin, C. Lopez-Vicario, M. Lorente, P. L. Lorenzi, P. Lorincz, M. Los, M. T. Lotze, P. E. Lovat, B. Lu, B. Lu, J. Lu, Q. Lu, S. M. Lu, S. Lu, Y. Lu, F. Luciano, S. Luckhart, J. M. Lucocq, P. Ludovico, A. Lugea, N. W. Lukacs, J. J. Lum, A. H. Lund, H. Luo, J. Luo, S. Luo, C. Luparello, T. Lyons, J. Ma, Y. Ma, Y. Ma, Z. Ma, J. Machado, G. M. Machado-Santelli, F. Macian, G. C. MacIntosh, J. P. MacKeigan, K. F. Macleod, J. D. MacMicking, L. A. MacMillan-Crow, F. Madeo, M. Madesh, J. Madrigal-Matute, A. Maeda, T. Maeda, G. Maegawa, E. Maellaro, H. Maes, M. Magarinos, K. Maiese, T. K. Maiti, L. Maiuri, M. C. Maiuri, C. G. Maki, R. Malli, W. Malorni, A. Maloyan, F. Mami-Chouaib, N. Man, J. D. Mancias, E. M. Mandelkow, M. A. Mandell, A. A. Manfredi, S. N. Manie, C. Manzoni, K. Mao, Z. Mao, Z. W. Mao, P. Marambaud, A. M. Marconi, Z. Marelja, G. Marfe, M. Margeta, E. Margittai, M. Mari, F. V. Mariani, C. Marin, S. Marinelli, G. Marino, I. Markovic, R. Marquez, A. M. Martelli, S. Martens, K. R. Martin, S. J. Martin, S. Martin, M. A. Martin-Acebes, P. Martin-Sanz, C. Martinand-Mari, W. Martinet, J. Martinez, N. Martinez-Lopez, U. Martinez-Outschoorn, M. Martinez-Velazquez, M. Martinez-Vicente, W. K. Martins, H. Mashima, J. A. Mastroianni, G. Matarese, P. Matarrese, R. Mateo, S. Matoba, N. Matsumoto, T. Matsushita, A. Matsuura, T. Matsuzawa, M. P. Mattson, S. Matus, N. Maugeri, C. Mauvezin, A. Mayer, D. Maysinger, G. D. Mazzolini, M.

- K. McBrayer, K. McCall, C. McCormick, G. M. McInerney, S. C. McIver, S. McKenna, J. J. McMahon, I. A. McNeish, F. Mechta-Grigoriou, J. P. Medema, D. L. Medina, K. Megyeri, M. Mehrpour, J. L. Mehta, Y. Mei, U. C. Meier, A. J. Meijer, A. Melendez, G. Melino, S. Melino, E. J. de Melo, M. A. Mena, M. D. Meneghini, J. A. Menendez, R. Menezes, L. Meng, L. H. Meng, S. Meng, R. Menghini, A. S. Menko, R. F. Menna-Barreto, M. B. Menon, M. A. Meraz-Rios, G. Merla, L. Merlini, A. M. Merlot, A. Meryk, S. Meschini, J. N. Meyer, M. T. Mi, C. Y. Miao, L. Micale, S. Michaeli, C. Michiels, A. R. Migliaccio, A. S. Mihailidou, D. Mijaljica, K. Mikoshiba, E. Milan, L. Miller-Fleming, G. B. Mills, I. G. Mills, G. Minakaki, B. A. Minassian, X. F. Ming, F. Minibayeva, E. A. Minina, J. D. Minter, S. Minucci, A. Miranda-Vizute, C. H. Mitchell, S. Miyamoto, K. Miyazawa, N. Mizushima, K. Mnich, B. Mograbi, S. Mohseni, L. F. Moita, M. Molinari, M. Molinari, A. B. Moller, B. Mollereau, F. Mollinedo, M. Mongillo, M. M. Monick, S. Montagnaro, C. Montell, D. J. Moore, M. N. Moore, R. Mora-Rodriguez, P. I. Moreira, E. Morel, M. B. Morelli, S. Moreno, M. J. Morgan, A. Moris, Y. Moriyasu, J. L. Morrison, L. A. Morrison, E. Morselli, J. Moscat, P. L. Moseley, S. Mostowy, E. Motori, D. Mottet, J. C. Mottram, C. E. Moussa, V. E. Mpakou, H. Mukhtar, J. M. Mulcahy Levy, S. Muller, R. Munoz-Moreno, C. Munoz-Pinedo, C. Munz, M. E. Murphy, J. T. Murray, A. Murthy, I. U. Mysorekar, I. R. Nabi, M. Nabissi, G. A. Nader, Y. Nagahara, Y. Nagai, K. Nagata, A. Nagelkerke, P. Nagy, S. R. Naidu, S. Nair, H. Nakano, H. Nakatogawa, M. Nanjundan, G. Napolitano, N. I. Naqvi, R. Nardacci, D. P. Narendra, M. Narita, A. C. Nascimbeni, R. Natarajan, L. C. Navegantes, S. T. Nawrocki, T. Y. Nazarko, V. Y. Nazarko, T. Neill, L. M. Neri, M. G. Netea, R. T. Netea-Maier, B. M. Neves, P. A. Ney, I. P. Nezis, H. T. Nguyen, H. P. Nguyen, A. S. Nicot, H. Nilsen, P. Nilsson, M. Nishimura, I. Nishino, M. Niso-Santano, H. Niu, R. A. Nixon, V. C. Njar, T. Noda, A. A. Noegel, E. M. Nolte, E. Norberg, K. K. Norga, S. K. Noreini, S. Notomi, L. Notterpek, K. Nowikovsky, N. Nukina, T. Nurnberger, V. B. O'Donnell, T. O'Donovan, P. J. O'Dwyer, I. Oehme, C. L. Oeste, M. Ogawa, B. Ogretmen, Y. Ogura, Y. J. Oh, M. Ohmuraya, T. Ohshima, R. Ojha, K. Okamoto, T. Okazaki, F. J. Oliver, K. Ollinger, S. Olsson, D. P. Orban, P. Ordonez, I. Orhon, L. Orosz, E. J. O'Rourke, H. Orozco, A. L. Ortega, E. Ortona, L. D. Osellame, J. Oshima, S. Oshima, H. D. Osiewacz, T. Otomo, K. Otsu, J. J. Ou, T. F. Outeiro, D. Y. Ouyang, H. Ouyang, M. Overholtzer, M. A. Ozburn, P. H. Ozdinler, B. Ozpolat, C. Pacelli, P. Paganetti, G. Page, G. Pages, U. Pagnini, B. Pajak, S. C. Pak, K. Pakos-Zebrucka, N. Pakpour, Z. Palkova, F. Palladino, K. Pallauf, N. Pallet, M. Palmieri, S. R. Paludan, C. Palumbo, S. Palumbo, O. Pampliega, H. Pan, W. Pan, T. Panaretakis, A. Pandey, A. Pantazopoulou, Z. Papackova, D. L. Papademetrio, I. Papassideri, A. Papini, N. Parajuli, J. Pardo, V. V. Parekh, G. Parenti, J. I. Park, J. Park, O. K. Park, R. Parker, R. Parlato, J. B. Parys, K. R. Parzych, J. M. Pasquet, B. Pasquier, K. B. Pasumarthi, D. Patschan, C. Patterson, S. Pattingre, S. Pattison, A. Pause, H. Pavenstadt, F. Pavone, Z. Pedrozo, F. J. Pena, M. A. Penalva, M. Pende, J. Peng, F. Penna, J. M. Penninger, A. Pensalfini, S. Pepe, G. J. Pereira, P. C. Pereira, V. Perez-de la Cruz, M. E. Perez-Perez, D. Perez-Rodriguez, D. Perez-Sala, C. Perier, A.

- Perl, D. H. Perlmutter, I. Perrotta, S. Pervaiz, M. Pesonen, J. E. Pessin, G. J. Peters, M. Petersen, I. Petrache, B. J. Petrof, G. Petrovski, J. M. Phang, M. Piacentini, M. Pierdominici, P. Pierre, V. Pierrefite-Carle, F. Pietrocola, F. X. Pimentel-Muinos, M. Pinar, B. Pineda, R. Pinkas-Kramarski, M. Pinti, P. Pinton, B. Piperdi, J. M. Piret, L. C. Plataniias, H. W. Platta, E. D. Plowey, S. Poggeler, M. Poirot, P. Polcic, A. Poletti, A. H. Poon, H. Popelka, B. Popova, I. Poprawa, S. M. Poulouse, J. Poulton, S. K. Powers, T. Powers, M. Pozuelo-Rubio, K. Prak, R. Prange, M. Prescott, M. Priault, S. Prince, R. L. Proia, T. Proikas-Cezanne, H. Prokisch, V. J. Promponas, K. Przyklenk, R. Puertollano, S. Pugazhenth, L. Puglielli, A. Pujol, J. Puyal, D. Pyeon, X. Qi, W. B. Qian, Z. H. Qin, Y. Qiu, Z. Qu, J. Quadrilatero, F. Quinn, N. Raben, H. Rabinowich, F. Radogna, M. J. Ragusa, M. Rahmani, K. Raina, S. Ramanadham, R. Ramesh, A. Rami, S. Randall-Demllo, F. Randow, H. Rao, V. A. Rao, B. B. Rasmussen, T. M. Rasse, E. A. Ratovitski, P. E. Rautou, S. K. Ray, B. Razani, B. H. Reed, F. Reggiori, M. Rehm, A. S. Reichert, T. Rein, D. J. Reiner, E. Reits, J. Ren, X. Ren, M. Renna, J. E. Reusch, J. L. Revuelta, L. Reyes, A. R. Rezaie, R. I. Richards, D. R. Richardson, C. Richetta, M. A. Riehle, B. H. Rihn, Y. Rikihisa, B. E. Riley, G. Rimbach, M. R. Rippo, K. Ritis, F. Rizzi, E. Rizzo, P. J. Roach, J. Robbins, M. Roberge, G. Roca, M. C. Roccheri, S. Rocha, C. M. Rodrigues, C. I. Rodriguez, S. R. de Cordoba, N. Rodriguez-Muela, J. Roelofs, V. V. Rogov, T. T. Rohn, B. Rohrer, D. Romanelli, L. Romani, P. S. Romano, M. I. Roncero, J. L. Rosa, A. Rosello, K. V. Rosen, P. Rosenstiel, M. Rost-Roszkowska, K. A. Roth, G. Roue, M. Rouis, K. M. Rouschop, D. T. Ruan, D. Ruano, D. C. Rubinsztein, E. B. Rucker, 3rd, A. Rudich, E. Rudolf, R. Rudolf, M. A. Ruegg, C. Ruiz-Roldan, A. A. Ruparelia, P. Rusmini, D. W. Russ, G. L. Russo, G. Russo, R. Russo, T. E. Rusten, V. Ryabovol, K. M. Ryan, S. W. Ryter, D. M. Sabatini, M. Sacher, C. Sachse, M. N. Sack, J. Sadoshima, P. Saftig, R. Sagi-Eisenberg, S. Sahni, P. Saikumar, T. Saito, T. Saitoh, K. Sakakura, M. Sakoh-Nakatogawa, Y. Sakuraba, M. Salazar-Roa, P. Salomoni, A. K. Saluja, P. M. Salvaterra, R. Salvioli, A. Samali, A. M. Sanchez, J. A. Sanchez-Alcazar, R. Sanchez-Prieto, M. Sandri, M. A. Sanjuan, S. Santaguida, L. Santambrogio, G. Santoni, C. N. Dos Santos, S. Saran, M. Sardiello, G. Sargent, P. Sarkar, S. Sarkar, M. R. Sarrias, M. M. Sarwal, C. Sasakawa, M. Sasaki, M. Sass, K. Sato, M. Sato, J. Satriano, N. Savaraj, S. Saveljeva, L. Schaefer, U. E. Schaible, M. Scharl, H. M. Schatzl, R. Schekman, W. Scheper, A. Schiavi, H. M. Schipper, H. Schmeisser, J. Schmidt, I. Schmitz, B. E. Schneider, E. M. Schneider, J. L. Schneider, E. A. Schon, M. J. Schonenberger, A. H. Schonthal, D. F. Schorderet, B. Schroder, S. Schuck, R. J. Schulze, M. Schwarten, T. L. Schwarz, S. Sciarretta, K. Scotto, A. I. Scovassi, R. A. Screatton, M. Screen, H. Seca, S. Sedej, L. Segatori, N. Segev, P. O. Seglen, J. M. Segui-Simarro, J. Segura-Aguilar, E. Seki, C. Sell, I. Selliez, C. F. Semenkovich, G. L. Semenza, U. Sen, A. L. Serra, A. Serrano-Puebla, H. Sesaki, T. Setoguchi, C. Settembre, J. J. Shacka, A. N. Shajahan-Haq, I. M. Shapiro, S. Sharma, H. She, C. J. Shen, C. C. Shen, H. M. Shen, S. Shen, W. Shen, R. Sheng, X. Sheng, Z. H. Sheng, T. G. Shepherd, J. Shi, Q. Shi, Q. Shi, Y. Shi, S. Shibutani, K. Shibuya, Y. Shidoji, J. J. Shieh, C. M. Shih, Y. Shimada, S.

- Shimizu, D. W. Shin, M. L. Shinohara, M. Shintani, T. Shintani, T. Shioi, K. Shirabe, R. Shiri-Sverdlov, O. Shirihai, G. C. Shore, C. W. Shu, D. Shukla, A. A. Sibirny, V. Sica, C. J. Sigurdson, E. M. Sigurdsson, P. S. Sijwali, B. Sikorska, W. A. Silveira, S. Silvente-Poirot, G. A. Silverman, J. Simak, T. Simmet, A. K. Simon, H. U. Simon, C. Simone, M. Simons, A. Simonsen, R. Singh, S. V. Singh, S. K. Singh, D. Sinha, S. Sinha, F. A. Sinicrope, A. Sirko, K. Sirohi, B. J. Sishi, A. Sittler, P. M. Siu, E. Sivridis, A. Skwarska, R. Slack, I. Slaninova, N. Slavov, S. S. Smaili, K. S. Smalley, D. R. Smith, S. J. Soenen, S. A. Soleimanpour, A. Solhaug, K. Somasundaram, J. H. Son, A. Sonawane, C. Song, F. Song, H. K. Song, J. X. Song, W. Song, K. Y. Soo, A. K. Sood, T. W. Soong, V. Soontornniyomkij, M. Sorice, F. Sotgia, D. R. Soto-Pantoja, A. Sotthibundhu, M. J. Sousa, H. P. Spaink, P. N. Span, A. Spang, J. D. Sparks, P. G. Speck, S. A. Spector, C. D. Spies, W. Springer, D. S. Clair, A. Stacchiotti, B. Staels, M. T. Stang, D. T. Starczynowski, P. Starokadomskyy, C. Steegborn, J. W. Steele, L. Stefanis, J. Steffan, C. M. Stellrecht, H. Stenmark, T. M. Stepkowski, S. T. Stern, C. Stevens, B. R. Stockwell, V. Stoka, Z. Storchova, B. Stork, V. Stratoulis, D. J. Stravopodis, P. Strnad, A. M. Strohecker, A. L. Strom, P. Stromhaug, J. Stulik, Y. X. Su, Z. Su, C. S. Subauste, S. Subramaniam, C. M. Sue, S. W. Suh, X. Sui, S. Sukserree, D. Sulzer, F. L. Sun, J. Sun, J. Sun, S. Y. Sun, Y. Sun, Y. Sun, Y. Sun, V. Sundaramoorthy, J. Sung, H. Suzuki, K. Suzuki, N. Suzuki, T. Suzuki, Y. J. Suzuki, M. S. Swanson, C. Swanton, K. Sward, G. Swarup, S. T. Sweeney, P. W. Sylvester, Z. Szatmari, E. Szegezdi, P. W. Szlosarek, H. Taegtmeier, M. Tafani, E. Taillebourg, S. W. Tait, K. Takacs-Vellai, Y. Takahashi, S. Takats, G. Takemura, N. Takigawa, N. J. Talbot, E. Tamagno, J. Tamburini, C. P. Tan, L. Tan, M. L. Tan, M. Tan, Y. J. Tan, K. Tanaka, M. Tanaka, D. Tang, D. Tang, G. Tang, I. Tanida, K. Tanji, B. A. Tannous, J. A. Tapia, I. Tasset-Cuevas, M. Tatar, I. Tavassoly, N. Tavernarakis, A. Taylor, G. S. Taylor, G. A. Taylor, J. P. Taylor, M. J. Taylor, E. V. Tchetchina, A. R. Tee, F. Teixeira-Clerc, S. Telang, T. Tencomnao, B. B. Teng, R. J. Teng, F. Terro, G. Tettamanti, A. L. Theiss, A. E. Theron, K. J. Thomas, M. P. Thome, P. G. Thomes, A. Thorburn, J. Thorner, T. Thum, M. Thumm, T. L. Thurston, L. Tian, A. Till, J. P. Ting, V. I. Titorenko, L. Toker, S. Toldo, S. A. Tooze, I. Topisirovic, M. L. Torgersen, L. Torosantucci, A. Torriglia, M. R. Torrisi, C. Tournier, R. Towns, V. Trajkovic, L. H. Travassos, G. Triola, D. N. Tripathi, D. Trisciuglio, R. Troncoso, I. P. Trougakos, A. C. Truttmann, K. J. Tsai, M. P. Tschan, Y. H. Tseng, T. Tsukuba, A. Tsung, A. S. Tsvetkov, S. Tu, H. Y. Tuan, M. Tucci, D. A. Tumbarello, B. Turk, V. Turk, R. F. Turner, A. A. Tveita, S. C. Tyagi, M. Ubukata, Y. Uchiyama, A. Udelnow, T. Ueno, M. Umekawa, R. Umemiya-Shirafuji, B. R. Underwood, C. Ungermann, R. P. Ureshino, R. Ushioda, V. N. Uversky, N. L. Uzategui, T. Vaccari, M. I. Vaccaro, L. Vachova, H. Vakifahmetoglu-Norberg, R. Valdor, E. M. Valente, F. Vallette, A. M. Valverde, G. Van den Berghe, L. Van Den Bosch, G. R. van den Brink, F. G. van der Goot, I. J. van der Klei, L. J. van der Laan, W. G. van Doorn, M. van Egmond, K. L. van Golen, L. Van Kaer, M. van Lookeren Campagne, P. Vandenabeele, W. Vandenberghe, I. Vanhorebeek, I. Varela-Nieto, M. H. Vasconcelos, R.

- Vasko, D. G. Vavvas, I. Vega-Naredo, G. Velasco, A. D. Velentzas, P. D. Velentzas, T. Vellai, E. Vellenga, M. H. Vendelbo, K. Venkatachalam, N. Ventura, S. Ventura, P. S. Veras, M. Verdier, B. G. Vertessy, A. Viale, M. Vidal, H. Vieira, R. D. Vierstra, N. Vigneswaran, N. Vij, M. Vila, M. Villar, V. H. Villar, J. Villarroya, C. Vindis, G. Viola, M. T. Viscomi, G. Vitale, D. T. Vogl, O. V. Voitsekhovskaja, C. von Haefen, K. von Schwarzenberg, D. E. Voth, V. Vouret-Craviari, K. Vuori, J. M. Vyas, C. Waeber, C. L. Walker, M. J. Walker, J. Walter, L. Wan, X. Wan, B. Wang, C. Wang, C. Y. Wang, C. Wang, C. Wang, C. Wang, D. Wang, F. Wang, F. Wang, G. Wang, H. J. Wang, H. Wang, H. G. Wang, H. Wang, H. D. Wang, J. Wang, J. Wang, M. Wang, M. Q. Wang, P. Y. Wang, P. Wang, R. C. Wang, S. Wang, T. F. Wang, X. Wang, X. J. Wang, X. W. Wang, X. Wang, X. Wang, Y. Wang, Y. Wang, Y. Wang, Y. J. Wang, Y. Wang, Y. Wang, Y. T. Wang, Y. Wang, Z. N. Wang, P. Wappner, C. Ward, D. M. Ward, G. Warnes, H. Watada, Y. Watanabe, K. Watase, T. E. Weaver, C. D. Weekes, J. Wei, T. Weide, C. C. Weihl, G. Weindl, S. N. Weis, L. Wen, X. Wen, Y. Wen, B. Westermann, C. M. Weyand, A. R. White, E. White, J. L. Whitton, A. J. Whitworth, J. Wiels, F. Wild, M. E. Wildenberg, T. Wileman, D. S. Wilkinson, S. Wilkinson, D. Willbold, C. Williams, K. Williams, P. R. Williamson, K. F. Winklhofer, S. S. Witkin, S. E. Wohlgemuth, T. Wollert, E. J. Wolvetang, E. Wong, G. W. Wong, R. W. Wong, V. K. Wong, E. A. Woodcock, K. L. Wright, C. Wu, D. Wu, G. S. Wu, J. Wu, J. Wu, M. Wu, M. Wu, S. Wu, W. K. Wu, Y. Wu, Z. Wu, C. P. Xavier, R. J. Xavier, G. X. Xia, T. Xia, W. Xia, Y. Xia, H. Xiao, J. Xiao, S. Xiao, W. Xiao, C. M. Xie, Z. Xie, Z. Xie, M. Xilouri, Y. Xiong, C. Xu, C. Xu, F. Xu, H. Xu, H. Xu, J. Xu, J. Xu, J. Xu, L. Xu, X. Xu, Y. Xu, Y. Xu, Z. X. Xu, Z. Xu, Y. Xue, T. Yamada, A. Yamamoto, K. Yamanaka, S. Yamashina, S. Yamashiro, B. Yan, B. Yan, X. Yan, Z. Yan, Y. Yanagi, D. S. Yang, J. M. Yang, L. Yang, M. Yang, P. M. Yang, P. Yang, Q. Yang, W. Yang, W. Y. Yang, X. Yang, Y. Yang, Y. Yang, Z. Yang, Z. Yang, M. C. Yao, P. J. Yao, X. Yao, Z. Yao, Z. Yao, L. S. Yasui, M. Ye, B. Yedvobnick, B. Yeganeh, E. S. Yeh, P. L. Yeyati, F. Yi, L. Yi, X. M. Yin, C. K. Yip, Y. M. Yoo, Y. H. Yoo, S. Y. Yoon, K. I. Yoshida, T. Yoshimori, K. H. Young, H. Yu, J. J. Yu, J. T. Yu, J. Yu, L. Yu, W. H. Yu, X. F. Yu, Z. Yu, J. Yuan, Z. M. Yuan, B. Y. Yue, J. Yue, Z. Yue, D. N. Zacks, E. Zacksenhaus, N. Zaffaroni, T. Zaglia, Z. Zakeri, V. Zecchini, J. Zeng, M. Zeng, Q. Zeng, A. S. Zervos, D. D. Zhang, F. Zhang, G. Zhang, G. C. Zhang, H. Zhang, H. Zhang, H. Zhang, J. Zhang, J. Zhang, J. Zhang, J. P. Zhang, L. Zhang, L. Zhang, L. Zhang, L. Zhang, M. Y. Zhang, X. Zhang, X. D. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, M. Zhao, W. L. Zhao, X. Zhao, Y. G. Zhao, Y. Zhao, Y. Zhao, Y. X. Zhao, Z. Zhao, Z. J. Zhao, D. Zheng, X. L. Zheng, X. Zheng, B. Zhivotovsky, Q. Zhong, G. Z. Zhou, G. Zhou, H. Zhou, S. F. Zhou, X. J. Zhou, H. Zhu, H. Zhu, W. G. Zhu, W. Zhu, X. F. Zhu, Y. Zhu, S. M. Zhuang, X. Zhuang, E. Ziparo, C. E. Zois, T. Zoladek, W. X. Zong, A. Zorzano and S. M. Zughaier: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, 12(1), 1-222 (2016)
DOI: 10.1080/15548627.2015.1100356
150. K. Maiese: Autophagy to the Rescue. *Curr Neurovasc Res*, 14(3), 199 (2017)
DOI: 10.2174/156720261466617-0724160119

151. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Targeting disease through novel pathways of apoptosis and autophagy. *Expert Opin Ther Targets*, 16(12), 1203-14 (2012)
DOI: 10.1517/14728222.2012.719499
152. J. Hou, Z. Z. Chong, Y. C. Shang and K. Maiese: Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. *Curr Neurovasc Res*, 7(2), 95-112 (2010)
DOI: 10.2174/156720210791184899
153. K. Maiese and A. M. Vincent: Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. *J Neurosci Res*, 59(4), 568-80 (2000)
154. K. Schutters and C. Reutelingsperger: Phosphatidylserine targeting for diagnosis and treatment of human diseases. *Apoptosis*, 15(9), 1072-82 (2010)
155. Y. C. Shang, Z. Z. Chong, J. Hou and K. Maiese: Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. *Cell Signal*, 22(9), 1317-29 (2010)
156. G. B. Taveira, E. O. Mello, S. B. Souza, R. M. Monteiro, A. C. Ramos, A. O. Carvalho, R. Rodrigues, L. A. Okorokov and V. M. Gomes: Programmed cell death in yeast by thionin-like peptide from *Capsicum annuum* fruits involving activation of capases and extracellular H(+) flux. *Biosci Rep* (2018)
DOI: 10.1042/bsr20180119
157. L. Wei, C. Sun, M. Lei, G. Li, L. Yi, F. Luo, Y. Li, L. Ding, Z. Liu, S. Li and P. Xu: Activation of Wnt/beta-catenin Pathway by Exogenous Wnt1 Protects SH-SY5Y Cells Against 6-Hydroxydopamine Toxicity. *J Mol Neurosci*, 49(1), 105-15 (2013)
DOI: 10.1007/s12031-012-9900-8
158. C. J. Williams and D. T. Dexter: Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease. *J Neurochem*, 129(1), 4-20 (2014)
DOI: 10.1111/jnc.12608
159. J. Hou, S. Wang, Y. C. Shang, Z. Z. Chong and K. Maiese: Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress. *Curr Neurovasc Res*, 8(3), 220-35 (2011)
160. S. Kim, I. H. Kang, J. B. Nam, Y. Cho, D. Y. Chung, S. H. Kim, J. S. Kim, Y. D. Cho, E. K. Hong, N. W. Sohn and J. W. Shin: Ameliorating the Effect of Astragaloside IV on Learning and Memory Deficit after Chronic Cerebral Hypoperfusion in Rats. *Molecules*, 20(2), 1904-21 (2015)
DOI: 10.3390/molecules20021904
161. S. L. Liu, H. X. Lin, C. Y. Lin, X. Q. Sun, L. P. Ye, F. Qiu, W. Wen, X. Hua, X. Q. Wu, J. Li, L. B. Song and L. Guo: TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/beta-catenin signaling pathway and promoting the epithelial mesenchymal transition. *Cancer Lett*, 402, 117-130 (2017)
DOI: 10.1016/j.canlet.2017.05.022
162. Y. Lu, T. Shen, H. Yang and W. Gu: Ruthenium Complexes Induce HepG2 Human Hepatocellular Carcinoma Cell Apoptosis and Inhibit Cell Migration and Invasion through Regulation of the Nrf2

- Pathway. *Int J Mol Sci*, 17(5) (2016)
DOI: 10.3390/ijms17050775
163. K. Maiese: The Many Facets of Cell Injury: Angiogenesis to Autophagy. *Curr Neurovasc Res*, 9(2), 1-2 (2012)
164. C. Dai, G. D. Ciccotosto, R. Cappai, Y. Wang, S. Tang, D. Hoyer, E. K. Schneider, T. Velkov and X. Xiao: Rapamycin confers neuroprotection against colistin-induced oxidative stress, mitochondria dysfunction and apoptosis through the activation of autophagy and mTOR/Akt/CREB signaling pathways. *ACS Chem Neurosci*, 9(4), 824-837 (2017)
DOI: 10.1021/acscchemneuro.7b00323
165. C. Ding, J. Zhang, B. Li, Z. Ding, W. Cheng, F. Gao, Y. Zhang, Y. Xu and S. Zhang: Cornin protects SHSY5Y cells against oxygen and glucose deprivation-induced autophagy through the PI3K/Akt/mTOR pathway. *Mol Med Rep*, 17(1), 87-92 (2017)
DOI: 10.3892/mmr.2017.7864
166. C. Gao, H. Yu, C. Yan, W. Zhao, Y. Liu, D. Zhang, J. Li and N. Liu: X-linked inhibitor of apoptosis inhibits apoptosis and preserves the blood-brain barrier after experimental subarachnoid hemorrhage. *Sci Rep*, 7, 44918 (2017)
DOI: 10.1038/srep44918
167. A. Park and H. C. Koh: NF-kappaB/mTOR-mediated autophagy can regulate diquat-induced apoptosis. *Arch Toxicol* (2019)
DOI: 10.1007/s00204-019-02424-7
168. T. J. Bailey, S. L. Fossum, S. M. Fimbel, J. E. Montgomery and D. R. Hyde: The inhibitor of phagocytosis, O-phospho-L-serine, suppresses Muller glia proliferation and cone cell regeneration in the light-damaged zebrafish retina. *Exp Eye Res*, 91(5), 601-12 (2010)
DOI: 10.1016/j.exer.2010.07.017
169. Y. C. Shang, Z. Z. Chong, J. Hou and K. Maiese: FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. *Curr Neurovasc Res*, 6(4), 223-38 (2009)
170. Y. J. Xin, B. Yuan, B. Yu, Y. Q. Wang, J. J. Wu, W. H. Zhou and Z. Qiu: Tet1-mediated DNA demethylation regulates neuronal cell death induced by oxidative stress. *Sci Rep*, 5, 7645 (2015)
DOI: 10.1038/srep07645
171. T. Yu, L. Li, T. Chen, Z. Liu, H. Liu and Z. Li: Erythropoietin attenuates advanced glycation endproducts-induced toxicity of schwann cells *in vitro*. *Neurochem Res*, 40(4), 698-712 (2015)
DOI: 10.1007/s11064-015-1516-2
172. K. Maiese: FoxO Proteins in the Nervous System. *Anal Cell Pathol (Amst)*, 2015, 569392 (2015)
DOI: 10.1155/2015/569392
173. T. Bombeli, A. Karsan, J. F. Tait and J. M. Harlan: Apoptotic vascular endothelial cells become procoagulant. *Blood*, 89(7), 2429-42 (1997)
174. Z. Z. Chong, J. Q. Kang and K. Maiese: Angiogenesis and plasticity: role of erythropoietin in vascular systems. *J Hematother Stem Cell Res*, 11(6), 863-71 (2002)
175. K. Maiese, Z. Z. Chong and Y. C. Shang: Raves and risks for erythropoietin. *Cytokine Growth Factor Rev*, 19(2), 145-

- 155 (2008)
DOI: S1359-6101(08)00006-3
176. S. H. Lin, Z. Z. Chong and K. Maiese: Nicotinamide: A Nutritional Supplement that Provides Protection Against Neuronal and Vascular Injury. *J Med Food*, 4(1), 27-38 (2001)
177. K. Maiese, S. Lin and Z. Z. Chong: Elucidating neuronal and vascular injury through the cytoprotective agent nicotinamide. *Curr Med Chem-Imm, Endoc. & Metab. Agents*, 1(3), 257-267 (2001)
178. P. O. Koh: Nicotinamide attenuates the injury-induced decrease of hippocalcin in ischemic brain injury. *Neurosci Lett*, 545, 6-10 (2013)
DOI: 10.1016/j.neulet.2013.04.010
179. F. Lin, W. Xu, C. Guan, M. Zhou, W. Hong, L. Fu, D. Liu and A. Xu: Niacin protects against UVB radiation-induced apoptosis in cultured human skin keratinocytes. *Int J Mol Med*, 29(4), 593-600 (2012)
DOI: 10.3892/ijmm.2012.886
180. C. Zhao, W. Li, H. Duan, Z. Li, Y. Jia, S. Zhang, X. Wang, Q. Zhou and W. Shi: NAD(+) precursors protect corneal endothelial cells from UVB-induced apoptosis. *Am J Physiol Cell Physiol* (2020)
DOI: 10.1152/ajpcell.00445.2019
181. A. Peresypkina, A. Pazhinsky, L. Danilenko, S. Lugovskoy, M. Pokrovskii, E. Beskhmel'nitsyna, N. Solov'ev, A. Pobeda, M. Korokin, E. Levkova, V. Gubareva, L. Korokina, O. Martynova, V. Soldatov and V. Pokrovskii: Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate. *Biology (Basel)*, 9(3) (2020)
DOI: 10.3390/biology9030045
182. W. Y. Li, J. H. Ren, N. N. Tao, L. K. Ran, X. Chen, H. Z. Zhou, B. Liu, X. S. Li, A. L. Huang and J. Chen: The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication *in vitro* and *in vivo*. *Arch Virol* (2015)
DOI: 10.1007/s00705-015-2712-8
183. S. Preau, M. Ambler, A. Sigurta, A. Kleyman, A. Dyson, N. E. Hill, E. Boulanger and M. Singer: Protein recycling and limb muscle recovery after critical illness in slow- and fast-twitch limb muscle. *Am J Physiol Regul Integr Comp Physiol* (2019)
DOI: 10.1152/ajpregu.00221.2018
184. Y. Wang and W. D. Le: Autophagy and Ubiquitin-Proteasome System. *Adv Exp Med Biol*, 1206, 527-550 (2019)
DOI: 10.1007/978-981-15-0602-4_25
185. N. Zhang and Y. Zhao: Other Molecular Mechanisms Regulating Autophagy. *Adv Exp Med Biol*, 1206, 261-271 (2019)
DOI: 10.1007/978-981-15-0602-4_13
186. C. Chen, Y. Lu, H. M. Siu, J. Guan, L. Zhu, S. Zhang, J. Yue and L. Zhang: Identification of Novel Vacuolin-1 Analogues as Autophagy Inhibitors by Virtual Drug Screening and Chemical Synthesis. *Molecules*, 22(6) (2017)
DOI: 10.3390/molecules22060891
187. M. Di Rosa, G. Distefano, C. Gagliano, D. Rusciano and L. Malaguarnera: Autophagy in Diabetic Retinopathy. *Curr Neuropharmacol*, 14(8), 810-825 (2016)
188. K. Maiese: Driving neural regeneration through the mammalian target of rapamycin. *Neural Regen Res*, 9(15),

- 1413-7 (2014)
DOI: 10.4103/1673-5374.139453
189. C. R. White, G. Datta and S. Giordano: High-Density Lipoprotein Regulation of Mitochondrial Function. *Adv Exp Med Biol*, 982, 407-429 (2017)
DOI: 10.1007/978-3-319-55330-6_22
190. T. E. Moors, J. J. Hoozemans, A. Ingrassia, T. Beccari, L. Parnetti, M. C. Chartier-Harlin and W. D. van de Berg: Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. *Mol Neurodegener*, 12(1), 11 (2017)
DOI: 10.1186/s13024-017-0154-3
191. E. P. Ratliff, R. E. Mauntz, R. W. Kotzebue, A. Gonzalez, M. Achal, A. Barekat, K. A. Finley, J. M. Sparhawk, J. E. Robinson, D. R. Herr, G. L. Harris, W. J. Joiner and K. D. Finley: Aging and Autophagic Function Influences the Progressive Decline of Adult Drosophila Behaviors. *PLoS One*, 10(7), e0132768 (2015)
DOI: 10.1371/journal.pone.0132768
192. P. B. Crino: The mTOR signalling cascade: paving new roads to cure neurological disease. *Nat Rev Neurol*, 12(7), 379-92 (2016)
DOI: 10.1038/nrneurol.2016.81
193. C. F. Hsieh, C. K. Liu, C. T. Lee, L. E. Yu and J. Y. Wang: Acute glucose fluctuation impacts microglial activity, leading to inflammatory activation or self-degradation. *Sci Rep*, 9(1), 840 (2019)
DOI: 10.1038/s41598-018-37215-0
194. M. Hu, Z. Liu, P. Lv, H. Wang, Y. Zhu, Q. Qi, J. Xu and L. Gao: Nimodipine activates neuroprotective signaling events and inactivates autophages in the VCID rat hippocampus. *Neurol Res*, 39(10), 904-909 (2017)
DOI: 10.1080/01616412.2017.1356157
195. K. Maiese: Forkhead transcription factors: new considerations for alzheimer's disease and dementia. *J Transl Sci*, 2(4), 241-247 (2016)
196. K. Maiese: Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss. *Curr Neurovasc Res*, 14(4), 415-420 (2017)
DOI: 10.2174/1567202614666171116102911
197. J. Cheng, B. J. North, T. Zhang, X. Dai, K. Tao, J. Guo and W. Wei: The emerging roles of protein homeostasis-governing pathways in Alzheimer's disease. *Aging Cell*, 17(5), e12801 (2018)
DOI: 10.1111/accel.12801
198. K. Han, N. Jia, Y. Zhong and X. Shang: S14G-humanin alleviates insulin resistance and increases autophagy in neurons of APP/PS1 transgenic mouse. *J Cell Biochem* (2017)
DOI: 10.1002/jcb.26452
199. L. Li: The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway. *CNS Drugs*, 31(7), 535-549 (2017)
DOI: 10.1007/s40263-017-0431-2
200. S. Saleem and S. C. Biswas: Tribbles Pseudokinase 3 Induces Both Apoptosis and Autophagy in Amyloid-beta-induced Neuronal Death. *J Biol Chem*, 292(7), 2571-2585 (2017)
DOI: 10.1074/jbc.M116.744730
201. Z. H. Zhang, Q. Y. Wu, R. Zheng, C. Chen, Y. Chen, Q. Liu, P. R. Hoffmann,

- J. Z. Ni and G. L. Song: Selenomethionine mitigates cognitive decline by targeting both tau hyperphosphorylation and autophagic clearance in an Alzheimer's disease mouse model. *J Neurosci*, 37(9), 2449-2462 (2017)
DOI: 10.1523/jneurosci.3229-16.2017
202. J. H. Lee, L. Tecedor, Y. H. Chen, A. M. Monteys, M. J. Sowada, L. M. Thompson and B. L. Davidson: Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes. *Neuron*, 85(2), 303-15 (2015)
DOI: 10.1016/j.neuron.2014.12.019
203. K. Maiese: The mechanistic target of rapamycin (mTOR) and the silent mating-type information regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders. *Biochem Soc Trans*, 46(2), 351-360 (2018)
DOI: 10.1042/bst20170121
204. R. L. Vidal, A. Figueroa, F. A. Court, P. Thielen, C. Molina, C. Wirth, B. Caballero, R. Kiffin, J. Segura-Aguilar, A. M. Cuervo, L. H. Glimcher and C. Hetz: Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy. *Hum Mol Genet*, 21(10), 2245-62 (2012)
DOI: 10.1093/hmg/dds040
205. J. Tong, Y. Lai, Y. A. Yao, X. J. Wang, Y. S. Shi, H. J. Hou, J. Y. Gu, F. Chen and X. B. Liu: Qiliqiangxin Rescues Mouse Cardiac Function by Regulating AGTR1/TRPV1-Mediated Autophagy in STZ-Induced Diabetes Mellitus. *Cell Physiol Biochem*, 47(4), 1365-1376 (2018)
DOI: 10.1159/000490822
206. J. Han, S. Shi, L. Min, T. Wu, W. Xia and W. Ying: NAD(+) Treatment Induces Delayed Autophagy in Neuro2a Cells Partially by Increasing Oxidative Stress. *Neurochem Res*, 36(12), 2270-7 (2011)
DOI: 10.1007/s11064-011-0551-x
207. S. W. Kim, J. H. Lee, J. H. Moon, U. M. Nazim, Y. J. Lee, J. W. Seol, J. Hur, S. K. Eo, J. H. Lee and S. Y. Park: Niacin alleviates TRAIL-mediated colon cancer cell death via autophagy flux activation. *Oncotarget*, 7(4), 4356-68 (2016)
DOI: 10.18632/oncotarget.5374
208. M. Ferrucci, F. Biagioni, L. Ryskalin, F. Limanaqi, S. Gambardella, A. Frati and F. Fornai: Ambiguous Effects of Autophagy Activation Following Hypoperfusion/Ischemia. *Int J Mol Sci*, 19(9) (2018)
DOI: 10.3390/ijms19092756
209. B. H. Wang, Q. Hou, Y. Q. Lu, M. M. Jia, T. Qiu, X. H. Wang, Z. X. Zhang and Y. Jiang: Ketogenic diet attenuates neuronal injury via autophagy and mitochondrial pathways in pentylenetetrazol-kindled seizures. *Brain Res* (2017)
DOI: 10.1016/j.brainres.2017.10.009
210. C. Shen, X. Dou, Y. Ma, W. Ma, S. Li and Z. Song: Nicotinamide protects hepatocytes against palmitate-induced lipotoxicity via SIRT1-dependent autophagy induction. *Nutr Res*, 40, 40-47 (2017)
DOI: 10.1016/j.nutres.2017.03.005
211. W. Li, L. Zhu, Z. B. Ruan, M. X. Wang, Y. Ren and W. Lu: Nicotinamide protects chronic hypoxic myocardial cells through regulating mTOR pathway and inducing autophagy. *Eur Rev Med Pharmacol Sci*, 23(12), 5503-5511 (2019)

- DOI: 10.26355/eurrev_201906_18220
212. K. Maiese: Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors. *Curr Neurovasc Res*, 15(1), 81-91 (2018)
DOI: 10.2174/1567202615666-180319151244
 213. Z. Z. Chong, Y. C. Shang, S. Wang and K. Maiese: Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. *Prog Neurobiol*, 99(2), 128-148 (2012)
DOI: 10.1016/j.pneurobio.2012.08.001
 214. H. Jesko, A. Stepien, W. J. Lukiw and R. P. Strosznajder: The Cross-Talk Between Sphingolipids and Insulin-Like Growth Factor Signaling: Significance for Aging and Neurodegeneration. *Mol Neurobiol*, 56(5), 3501-3521 (2019)
DOI: 10.1007/s12035-018-1286-3
 215. K. Maiese: Molecules to Medicine with mTOR: Translating Critical Pathways into Novel Therapeutic Strategies. *Elsevier and Academic Press*, ISBN 9780128027332 (2016)
 216. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: mTOR: on target for novel therapeutic strategies in the nervous system. *Trends Mol Med*, 19(1), 51-60 (2013)
DOI: 10.1016/j.molmed.2012.11.001
 217. J. Heitman, N. R. Movva and M. N. Hall: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science*, 253(5022), 905-9 (1991)
 218. S. K. Hwang and H. H. Kim: The functions of mTOR in ischemic diseases. *BMB Rep*, 44(8), 506-11 (2011)
 219. K. Maiese: Erythropoietin and mTOR: A "One-Two Punch" for Aging-Related Disorders Accompanied by Enhanced Life Expectancy. *Curr Neurovasc Res*, 13(4), 329-340 (2016)
 220. P. B. Martinez de Morentin, N. Martinez-Sanchez, J. Roa, J. Ferno, R. Nogueiras, M. Tena-Sempere, C. Dieguez and M. Lopez: Hypothalamic mTOR: the rookie energy sensor. *Curr Mol Med*, 14(1), 3-21 (2014)
 221. K. Maiese: Taking aim at Alzheimer's disease through the mammalian target of rapamycin. *Ann Med*, 46(8), 587-596 (2014)
DOI: 10.3109/07853890.2014.941921
 222. Q. Xue, J. A. Nagy, E. J. Manseau, T. L. Phung, H. F. Dvorak and L. E. Benjamin: Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. *Arterioscler Thromb Vasc Biol*, 29(8), 1172-8 (2009)
 223. K. G. Foster, H. A. Acosta-Jaquez, Y. Romeo, B. Ekim, G. A. Soliman, A. Carriere, P. P. Roux, B. A. Ballif and D. C. Fingar: Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. *J Biol Chem*, 285(1), 80-94 (2010)
 224. L. Wang, J. C. Lawrence, Jr., T. W. Sturgill and T. E. Harris: Mammalian target of rapamycin complex 1 (mTORC1) activity is associated with phosphorylation of raptor by mTOR. *J Biol Chem*, 284(22), 14693-7 (2009)
 225. T. R. Peterson, M. Laplante, C. C. Thoreen, Y. Sancak, S. A. Kang, W. M. Kuehl, N. S. Gray and D. M. Sabatini: DEPTOR is an mTOR inhibitor frequently

- overexpressed in multiple myeloma cells and required for their survival. *Cell*, 137(5), 873-86 (2009)
226. R. Malla, C. R. Ashby, Jr., N. K. Narayanan, B. Narayanan, J. S. Faridi and A. K. Tiwari: Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer. *Biochem Biophys Res Commun*, 463(3), 161-6 (2015)
DOI: 10.1016/j.bbrc.2015.05.041
227. Z. Z. Chong, Y. C. Shang, S. Wang and K. Maiese: PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection. *PLoS ONE*, 7(9), e45456 (2012)
DOI: 10.1371/journal.pone.0045456
228. B. D. Fonseca, E. M. Smith, V. H. Lee, C. MacKintosh and C. G. Proud: PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. *J Biol Chem*, 282(34), 24514-24 (2007)
229. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: WNT1 Inducible Signaling Pathway Protein 1 (WISP1) Targets PRAS40 to Govern beta-Amyloid Apoptotic Injury of Microglia. *Curr Neurovasc Res*, 9(4), 239-249 (2012)
230. H. Wang, Q. Zhang, Q. Wen, Y. Zheng, L. Philip, H. Jiang, J. Lin and W. Zheng: Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. *Cell Signal*, 24(1), 17-24 (2012)
DOI: 10.1016/j.cellsig.2011.08.010
231. X. Xiong, R. Xie, H. Zhang, L. Gu, W. Xie, M. Cheng, Z. Jian, K. Kovacina and H. Zhao: PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways. *Neurobiol Dis*, 66, 43-52 (2014)
DOI: 10.1016/j.nbd.2014.02.006
232. D. H. Kim, D. D. Sarbassov, S. M. Ali, R. R. Latek, K. V. Guntur, H. Erdjument-Bromage, P. Tempst and D. M. Sabatini: GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. *Mol Cell*, 11(4), 895-904 (2003)
233. D. A. Guertin, D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald and D. M. Sabatini: Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. *Dev Cell*, 11(6), 859-71 (2006)
234. E. Jacinto, R. Loewith, A. Schmidt, S. Lin, M. A. Ruegg, A. Hall and M. N. Hall: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. *Nat Cell Biol*, 6(11), 1122-8 (2004)
235. J. M. Garcia-Martinez and D. R. Alessi: mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). *Biochem J*, 416(3), 375-85 (2008)
236. L. R. Pearce, E. M. Sommer, K. Sakamoto, S. Wullschlegel and D. R. Alessi: Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. *Biochem J*, 436(1), 169-79 (2011)
237. L. L. Du, D. M. Chai, L. N. Zhao, X. H. Li, F. C. Zhang, H. B. Zhang, L. B. Liu, K.

- Wu, R. Liu, J. Z. Wang and X. W. Zhou: AMPK Activation Ameliorates Alzheimer's Disease-Like Pathology and Spatial Memory Impairment in a Streptozotocin-Induced Alzheimer's Disease Model in Rats. *J Alzheimers Dis*, 43(3), 775-84 (2015)
DOI: 10.3233/jad-140564
238. T. Jiang, J. T. Yu, X. C. Zhu, H. F. Wang, M. S. Tan, L. Cao, Q. Q. Zhang, L. Gao, J. Q. Shi, Y. D. Zhang and L. Tan: Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. *Br J Pharmacol*, 171(13), 3146-57 (2014)
DOI: 10.1111/bph.12655
239. P. Chakrabarti, T. English, J. Shi, C. M. Smas and K. V. Kandror: Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes*, 59(4), 775-81 (2010)
240. S. Hamada, K. Hara, T. Hamada, H. Yasuda, H. Moriyama, R. Nakayama, M. Nagata and K. Yokono: Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia. *Diabetes*, 58(6), 1321-32 (2009)
241. R. Malla, Y. Wang, W. K. Chan, A. K. Tiwari and J. S. Faridi: Genetic ablation of PRAS40 improves glucose homeostasis via linking the AKT and mTOR pathways. *Biochem Pharmacol* (2015)
DOI: 10.1016/j.bcp.2015.04.016
242. Y. Li, S. Xu, A. Giles, K. Nakamura, J. W. Lee, X. Hou, G. Donmez, J. Li, Z. Luo, K. Walsh, L. Guarente and M. Zang: Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. *Faseb J* (2011)
243. C. Treins, S. Alliouachene, R. Hassouna, Y. Xie, M. J. Birnbaum and M. Pende: The combined deletion of S6K1 and Akt2 deteriorates glycaemic control in high fat diet. *Mol Cell Biol* (2012)
DOI: 10.1128/mcb.00514-12
244. R. H. Wang, H. S. Kim, C. Xiao, X. Xu, O. Gavrilova and C. X. Deng: Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. *J Clin Invest*, 121(11), 4477-90 (2011)
DOI: 10.1172/jci46243
245. Y. Gu, J. Lindner, A. Kumar, W. Yuan and M. A. Magnuson: Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. *Diabetes*, 60(3), 827-37 (2011)
DOI: 10.2337/db10-1194
246. K. Maiese: Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease. *Curr Neurovasc Res*, 14(1), 82-88 (2017)
DOI: 10.2174/1567202613666-161129112822
247. C. A. Peixoto, W. H. de Oliveira, S. M. da Rocha Araujo and A. K. S. Nunes: AMPK activation: Role in the signaling pathways of neuroinflammation and neuro-degeneration. *Exp Neurol* (2017)
DOI: 10.1016/j.expneurol.2017.08.013
248. T. Sato, A. Nakashima, L. Guo and F. Tamanoi: Specific activation of mTORC1 by Rheb G-protein *in vitro* involves enhanced recruitment of its substrate

- protein. *J Biol Chem*, 284(19), 12783-91 (2009)
249. K. Inoki, T. Zhu and K. L. Guan: TSC2 mediates cellular energy response to control cell growth and survival. *Cell*, 115(5), 577-90 (2003)
250. Z. Z. Chong and K. Maiese: Mammalian Target of Rapamycin Signaling in Diabetic Cardiovascular Disease. *Cardiovasc Diabetol*, 11(1), 45 (2012)
DOI: 10.1186/1475-2840-11-45
251. J. Zhou, J. Wu, F. Zheng, M. Jin and H. Li: Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic betaTC-6 cells -1mTORbetaTC-6. *J Diabetes*, 7(2), 231-9 (2015)
DOI: 10.1111/1753-0407.12177
252. X. Y. Miao, Z. Y. Gu, P. Liu, Y. Hu, L. Li, Y. P. Gong, H. Shu, Y. Liu and C. L. Li: The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway. *Peptides*, 39, 71-9 (2013)
DOI: 10.1016/j.peptides.2012.10.006
253. Y. W. Liu, L. Zhang, Y. Li, Y. Q. Cheng, X. Zhu, F. Zhang and X. X. Yin: Activation of mTOR signaling mediates the increased expression of AChE in high glucose condition: *in vitro* and *in vivo* evidences. *Mol Neurobiol* (2015)
DOI: 10.1007/s12035-015-9425-6
254. M. C. Crespo, J. Tome-Carneiro, C. Pintado, A. Davalos, F. Visioli and E. Burgos-Ramos: Hydroxytyrosol restores proper insulin signaling in an astrocytic model of Alzheimer's disease. *Biofactors*, 43(4) (2017)
DOI: 10.1002/biof.1356
255. C. H. Jung, D. H. Lee, J. Ahn, H. Lee, W. H. Choi, Y. J. Jang and T. Y. Ha: gamma-Oryzanol Enhances Adipocyte Differentiation and Glucose Uptake. *Nutrients*, 7(6), 4851-4861 (2015)
DOI: 10.3390/nu7064851
256. E. Pasini, V. Flati, S. Paiardi, D. Rizzoni, E. Porteri, R. Aquilani, D. Assanelli, G. Corsetti, S. Specia, R. Rezzani, C. De Ciuceis and E. Agabiti-Rosei: Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. *Cardiovasc Diabetol*, 9, 46 (2010)
257. C. Chen, Y. Xu and Y. Song: IGF-1 gene-modified muscle-derived stem cells are resistant to oxidative stress via enhanced activation of IGF-1R/PI3K/AKT signaling and secretion of VEGF. *Mol Cell Biochem*, 386(1-2), 167-75 (2014)
DOI: 10.1007/s11010-013-1855-8
258. G. Nagel, R. S. Peter, A. Rosenbohm, W. Koenig, L. Dupuis, D. Rothenbacher and A. C. Ludolph: Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis - Results from the ALS Registry Swabia. *Sci Rep*, 10(1), 736 (2020)
DOI: 10.1038/s41598-020-57744-x
259. Z. Z. Chong, J. Q. Kang and K. Maiese: Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. *Circulation*, 106(23), 2973-9 (2002)
260. Z. Z. Chong, J. Q. Kang and K. Maiese: Apaf-1, Bcl-xL, Cytochrome c, and Caspase-9 Form the Critical Elements for Cerebral Vascular Protection by

- Erythropoietin. *J Cereb Blood Flow Metab*, 23(3), 320-30 (2003)
261. L. Cui, J. Guo, Q. Zhang, J. Yin, J. Li, W. Zhou, T. Zhang, H. Yuan, J. Zhao, L. Zhang, P. L. Carmichael and S. Peng: Erythropoietin activates SIRT1 to protect human cardiomyocytes against doxorubicin-induced mitochondrial dysfunction and toxicity. *Toxicol Lett*, 275, 28-38 (2017)
DOI: 10.1016/j.toxlet.2017.04.018
262. Q. Li, Y. Han, J. Du, H. Jin, J. Zhang, M. Niu and J. Qin: Recombinant Human Erythropoietin Protects Against Hippocampal Damage in Developing Rats with Seizures by Modulating Autophagy via the S6 Protein in a Time-Dependent Manner. *Neurochem Res* (2017)
DOI: 10.1007/s11064-017-2443-1
263. K. Maiese: Regeneration in the nervous system with erythropoietin. *Front Biosci (Landmark Ed)*, 21, 561-96 (2016)
264. K. Maiese: Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin. *Curr Neurovasc Res*, 14(2), 184-189 (2017)
DOI: 10.2174/1567202614666-170313105337
265. K. Maiese, F. Li and Z. Z. Chong: New avenues of exploration for erythropoietin. *Jama*, 293(1), 90-5 (2005)
DOI: 293/1/90
266. M. Shi, B. Flores, P. Li, N. Gillings, K. L. McMillan, J. Ye, L. J. Huang, S. S. Sidhu, Y. P. Zhong, M. T. Grompe, P. R. Streeter, O. W. Moe and M. C. Hu: Effects of Erythropoietin Receptor Activity on Angiogenesis, Tubular Injury and Fibrosis in Acute Kidney Injury: A "U-Shaped" Relationship. *Am J Physiol Renal Physiol*, ajprenal 00306 2017 (2017)
DOI: 10.1152/ajprenal.00306.2017
267. M. Vinberg, P. Hojman, B. K. Pedersen, L. V. Kessing and K. W. Miskowiak: Effects of erythropoietin on body composition and fat-glucose metabolism in patients with affective disorders. *Acta Neuropsychiatr*, 1-8 (2018)
DOI: 10.1017/neu.2018.16
268. S. Wang, C. Zhang, J. Li, S. Niyazi, L. Zheng, M. Xu, R. Rong, C. Yang and T. Zhu: Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization. *Cell Death Dis*, 8(4), e2725 (2017)
DOI: 10.1038/cddis.2017.104
269. T. Xu, H. Jin, Y. Lao, P. Wang, S. Zhang, H. Ruan, Q. Mao, L. Zhou, L. Xiao, P. Tong and C. Wu: Administration of erythropoietin prevents bone loss in osteonecrosis of the femoral head in mice. *Mol Med Rep*, 16(6), 8755-8762 (2017)
DOI: 10.3892/mmr.2017.7735
270. Y. B. Yu, K. H. Su, Y. R. Kou, B. C. Guo, K. I. Lee, J. Wei and T. S. Lee: Role of transient receptor potential vanilloid 1 in regulating erythropoietin-induced activation of endothelial nitric oxide synthase. *Acta Physiol (Oxf)*, 219(2), 465-477 (2017)
DOI: 10.1111/apha.12723
271. W. Jang, H. J. Kim, H. Li, K. D. Jo, M. K. Lee and H. O. Yang: The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy. *Mol*

- Neurobiol*, 53(6), 3812-3821 (2015)
DOI: 10.1007/s12035-015-9316-x
272. H. J. Lee, S. H. Koh, K. M. Song, I. J. Seol and H. K. Park: The Akt/mTOR/p70S6K Pathway Is Involved in the Neuroprotective Effect of Erythropoietin on Hypoxic/Ischemic Brain Injury in a Neonatal Rat Model. *Neonatology*, 110(2), 93-100 (2016)
DOI: 10.1159/000444360
273. K. Maiese, Z. Z. Chong, Y. C. Shang and S. Wang: Erythropoietin: new directions for the nervous system. *Int J Mol Sci*, 13(9), 11102-29 (2012)
DOI: 10.3390/ijms130911102
274. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. *Curr Neurovasc Res*, 8(4), 270-285 (2011)
275. Y. C. Shang, Z. Z. Chong, S. Wang and K. Maiese: Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. *Aging (Albany NY)*, 4(3), 187-201 (2012)
276. G. B. Wang, Y. L. Ni, X. P. Zhou and W. F. Zhang: The AKT/mTOR pathway mediates neuronal protective effects of erythropoietin in sepsis. *Mol Cell Biochem*, 385(1-2), 125-32 (2014)
DOI: 10.1007/s11010-013-1821-5
277. P. Esmaeili Tazangi, S. M. Moosavi, M. Shabani and M. Haghani: Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer's disease. *Pharmacol Biochem Behav*, 130, 15-21 (2015)
DOI: 10.1016/j.pbb.2014.12.011
278. Y. P. Li, G. J. Yang, L. Jin, H. M. Yang, J. Chen, G. S. Chai and L. Wang: Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid beta42 in mice. *Brain Res*, 1618, 159-67 (2015)
DOI: 10.1016/j.brainres.2015.05.031
279. J. Sun, J. M. Martin, V. Vanderpoel and R. K. Sumbria: The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease. *Neuromolecular Med* (2019)
DOI: 10.1007/s12017-019-08524-y
280. K. Maiese: Preserving Brain Function During Development and Aging with Erythropoietin. *Curr Neurovasc Res* (2019)
DOI: 10.2174/1567202616999-190821143340
281. Z. Z. Chong, J. Hou, Y. C. Shang, S. Wang and K. Maiese: EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a, GSK-3beta, and beta-Catenin to Foster Vascular Integrity During Experimental Diabetes. *Curr Neurovasc Res*, 8(2), 103-20 (2011)
282. Z. Z. Chong, Y. C. Shang and K. Maiese: Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. *Curr Neurovasc Res*, 4(3), 194-204 (2007)
283. D. Gradinaru, D. Margina, M. Ilie, C. Borsa, C. Ionescu and G. I. Prada: Correlation between erythropoietin serum levels and erythrocyte susceptibility to lipid peroxidation in elderly with type 2 diabetes. *Acta Physiol Hung*, 102(4), 400-8 (2015)
DOI: 10.1556/036.102.2015.4.7

284. S. Hamed, C. L. Bennett, C. Demiot, Y. Ullmann, L. Teot and A. Desmouliere: Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus. *Wound Repair Regen*, 22(1), 23-33 (2014)
DOI: 10.1111/wrr.12135
285. A. Montesano, A. R. Bonfigli, M. De Luca, P. Crocco, P. Garagnani, E. Marasco, C. Pirazzini, C. Giuliani, F. Romagnoli, C. Franceschi, G. Passarino, R. Testa, F. Olivieri and G. Rose: Erythropoietin (EPO) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes. *Sci Rep*, 9(1), 10395 (2019)
DOI: 10.1038/s41598-019-46894-2
286. H. S. Niu, C. H. Chang, C. S. Niu, J. T. Cheng and K. S. Lee: Erythropoietin ameliorates hyperglycemia in type 1-like diabetic rats. *Drug Des Devel Ther*, 10, 1877-84 (2016)
DOI: 10.2147/dddt.s105867
287. F. Gallyas, Jr., B. Sumegi and C. Szabo: Role of Akt Activation in PARP Inhibitor Resistance in Cancer. *Cancers (Basel)*, 12(3) (2020)
DOI: 10.3390/cancers12030532
288. Y. R. Pan, J. Y. Song, B. Fan, Y. Wang, L. Che, S. M. Zhang, Y. X. Chang, C. He and G. Y. Li: mTOR may interact with PARP-1 to regulate visible light-induced parthanatos in photoreceptors. *Cell Commun Signal*, 18(1), 27 (2020)
DOI: 10.1186/s12964-019-0498-0
289. M. S. Satoh and T. Lindahl: Role of poly(ADP-ribose) formation in DNA repair. *Nature*, 356(6367), 356-8 (1992)
290. J. Saldeen and N. Welsh: Nicotinamide-induced apoptosis in insulin producing cells is associated with cleavage of poly(ADP-ribose) polymerase. *Mol Cell Endocrinol*, 139(1-2), 99-107 (1998)
291. S. Love, R. Barber and G. K. Wilcock: Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. *Brain*, 122 (Pt 2), 247-53 (1999)
292. Y. F. Lai, L. Wang and W. Y. Liu: Nicotinamide pretreatment alleviates mitochondrial stress and protects hypoxic myocardial cells via AMPK pathway. *Eur Rev Med Pharmacol Sci*, 23(4), 1797-1806 (2019)
DOI: 10.26355/eurev_201902_17143
293. N. Moroz, J. J. Carmona, E. Anderson, A. C. Hart, D. A. Sinclair and T. K. Blackwell: Dietary restriction involves NAD - dependent mechanisms and a shift toward oxidative metabolism. *Aging Cell*, 13(6), 1075-1085 (2014)
DOI: 10.1111/accel.12273
294. P. Liu, X. Yang, C. Hei, Y. Meli, J. Niu, T. Sun and P. A. Li: Rapamycin Reduced Ischemic Brain Damage in Diabetic Animals Is Associated with Suppressions of mTOR and ERK1/2 Signaling. *Int J Biol Sci*, 12(8), 1032-40 (2016)
DOI: 10.7150/ijbs.15624
295. H. Zhao, Z. C. Wang, K. F. Wang and X. Y. Chen: Abeta peptide secretion is reduced by Radix Polygalae-induced autophagy via activation of the AMPK/mTOR pathway. *Mol Med Rep*, 12(2), 2771-2776 (2015)
DOI: 10.3892/mmr.2015.3781
296. K. Maiese: Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders. *Br J Clin Pharmacol*, 82(5), 1245-1266 (2016)

- DOI: 10.1111/bcp.12804
297. Y. Liu, R. Palanivel, E. Rai, M. Park, T. V. Gabor, M. P. Scheid, A. Xu and G. Sweeney: Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high fat diet feeding in mice. *Diabetes*, 64(1), 36-48 (2014)
DOI: 10.2337/db14-0267
 298. M. J. Stevens, F. Li, V. R. Drel, O. I. Abatan, H. Kim, D. Burnett, D. Larkin and I. G. Obrosova: Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. *J Pharmacol Exp Ther*, 320(1), 458-64 (2007)
 299. K. A. Weikel, J. M. Cacicedo, N. B. Ruderman and Y. Ido: Knockdown of GSK3 β Increases Basal Autophagy and AMPK Signaling in Nutrient-laden Human Aortic Endothelial Cells. *Biosci Rep*, 36(5), pii e00382 (2016)
DOI: 10.1042/bsr20160174
 300. Y. Dong, H. Chen, J. Gao, Y. Liu, J. Li and J. Wang: Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. *J Mol Cell Cardiol*, 136, 27-41 (2019)
DOI: 10.1016/j.yjmcc.2019.09.001
 301. H. Shokri Afra, M. Zangoeei, R. Meshkani, M. H. Ghahremani, D. Ilbeigi, A. Khedri, S. Shahmohamadnejad, S. Khaghani and M. Nourbakhsh: Hesperetin is a potent bioactivator that activates SIRT1-AMPK signaling pathway in HepG2 cells. *J Physiol Biochem* (2019)
DOI: 10.1007/s13105-019-00678-4
 302. D. Zhao, X. Sun, S. Lv, M. Sun, H. Guo, Y. Zhai, Z. Wang, P. Dai, L. Zheng, M. Ye and X. Wang: Salidroside attenuates oxidized lowdensity lipoproteininduced endothelial cell injury via promotion of the AMPK/SIRT1 pathway. *Int J Mol Med* (2019)
DOI: 10.3892/ijmm.2019.4153
 303. H. Zhang, X. Yang, X. Pang, Z. Zhao, H. Yu and H. Zhou: Genistein protects against ox-LDL-induced senescence through enhancing SIRT1/LKB1/AMPK-mediated autophagy flux in HUVECs. *Mol Cell Biochem*, 455(1) (2019)
DOI: 10.1007/s11010-018-3476-8
 304. A. Kalender, A. Selvaraj, S. Y. Kim, P. Gulati, S. Brule, B. Viollet, B. E. Kemp, N. Bardeesy, P. Dennis, J. J. Schlager, A. Marette, S. C. Kozma and G. Thomas: Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. *Cell Metab*, 11(5), 390-401 (2010)
DOI: 10.1016/j.cmet.2010.03.014
 305. C. He, H. Zhu, H. Li, M. H. Zou and Z. Xie: Dissociation of Bcl-2-Bec1 complex by activated AMPK enhances cardiac autophagy and protects against cardiomyocyte apoptosis in diabetes. *Diabetes*, 62(4), 1270-81 (2013)
DOI: 10.2337/db12-0533
 306. S. S. Oda: Metformin Protects against Experimental Acrylamide Neuropathy in Rats. *Drug Dev Res* (2017)
DOI: 10.1002/ddr.21400
 307. M. A. Zimmerman, C. D. Biggers and P. A. Li: Rapamycin treatment increases hippocampal cell viability in an mTOR-independent manner during exposure to hypoxia mimetic, cobalt chloride. *BMC Neurosci*, 19(1), 82 (2018)
DOI: 10.1186/s12868-018-0482-4
 308. P. Hu, D. Lai, P. Lu, J. Gao and H. He:

- ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells. *Int J Mol Med*, 29(4), 613-8 (2012)
DOI: 10.3892/ijmm.2012.891
309. Y. Lee, Y. Hong, S. R. Lee and K. T. Chang: Autophagy contributes to retardation of cardiac growth in diabetic rats. *Lab Anim Res*, 28(2), 99-107 (2012)
DOI: 10.5625/lar.2012.28.2.9.9
310. L. Martino, M. Masini, M. Novelli, P. Beffy, M. Bugliani, L. Marselli, P. Masiello, P. Marchetti and V. De Tata: Palmitate activates autophagy in INS-1E beta-cells and in isolated rat and human pancreatic islets. *PLoS ONE*, 7(5), e36188 (2012)
DOI: 10.1371/journal.pone.0036188
311. K. A. Kim, Y. J. Shin, M. Akram, E. S. Kim, K. W. Choi, H. Suh, C. H. Lee and O. N. Bae: High glucose condition induces autophagy in endothelial progenitor cells contributing to angiogenic impairment. *Biol Pharm Bull*, 37(7), 1248-52 (2014)
312. L. Wang, W. Wu, J. Chen, Y. Li, M. Xu and Y. Cai: miR122 and miR199 synergistically promote autophagy in oral lichen planus by targeting the Akt/mTOR pathway. *Int J Mol Med* (2019)
DOI: 10.3892/ijmm.2019.4068
313. M. Ka, A. L. Smith and W. Y. Kim: MTOR controls genesis and autophagy of GABAergic interneurons during brain development. *Autophagy*, 0 (2017)
DOI: 10.1080/15548627.2017.1327927
314. B. Yin, H. Liang, Y. Chen, K. Chu, L. Huang, L. Fang, E. Matro, W. Jiang and B. Luo: EGB1212 post-treatment ameliorates hippocampal CA1 neuronal death and memory impairment induced by transient global cerebral ischemia/reperfusion. *Am J Chin Med*, 41(6), 1329-41 (2013)
DOI: 10.1142/s0192415x13500894
315. M. Dorvash, M. Farahmandnia and I. Tavassoly: A Systems Biology Roadmap to Decode mTOR Control System in Cancer. *Interdiscip Sci*, 12(1), 1-11 (2020)
DOI: 10.1007/s12539-019-00347-6
316. K. Maiese: Dissecting the Biological Effects of Isoflurane through the Mechanistic Target of Rapamycin (mTOR) and microRNAs (miRNAs). *Curr Neurovasc Res*, 16(5) (2019)
DOI: 10.2174/1567202616999-191024151901
317. M. Fraenkel, M. Ketzinell-Gilad, Y. Ariav, O. Pappo, M. Karaca, J. Castel, M. F. Berthault, C. Magnan, E. Cerasi, N. Kaiser and G. Leibowitz: mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. *Diabetes*, 57(4), 945-57 (2008)
318. K. Sataranatarajan, Y. Ikeno, A. Bokov, D. Feliers, H. Yalamanchili, H. J. Lee, M. M. Mariappan, H. Tabatabai-Mir, V. Diaz, S. Prasad, M. A. Javors, G. Ghosh Choudhury, G. B. Hubbard, J. L. Barnes, A. Richardson and B. S. Kasinath: Rapamycin Increases Mortality in db/db Mice, a Mouse Model of Type 2 Diabetes. *J Gerontol A Biol Sci Med Sci*, 71(7), 850-857 (2016)
DOI: 10.1093/gerona/glv170
319. N. Deblon, L. Bourgoïn, C. Veyrat-Durebex, M. Peyrou, M. Vinciguerra, A. Caillon, C. Maeder, M. Fournier, X. Montet, F. Rohner-Jeanrenaud and M.

- Foti: Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. *Br J Pharmacol*, 165(7), 2325-40 (2012)
DOI: 10.1111/j.1476-5381.2011.01716.x
320. S. Kang, E. R. Chemaly, R. J. Hajjar and D. Lebeche: Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. *J Biol Chem*, 286(21), 18465-73 (2011)
321. A. Weckman, A. Di Ieva, F. Rotondo, L. V. Syro, L. D. Ortiz, K. Kovacs and M. D. Cusimano: Autophagy in the endocrine glands. *J Mol Endocrinol*, 52(2), R151-63 (2014)
DOI: 10.1530/jme-13-0241
322. Y. M. Lim, H. Lim, K. Y. Hur, W. Quan, H. Y. Lee, H. Cheon, D. Ryu, S. H. Koo, H. L. Kim, J. Kim, M. Komatsu and M. S. Lee: Systemic autophagy insufficiency compromises adaptation to metabolic stress and facilitates progression from obesity to diabetes. *Nat Commun*, 5, 4934 (2014)
DOI: 10.1038/ncomms5934
323. L. Ma, R. Fu, Z. Duan, J. Lu, J. Gao, L. Tian, Z. Lv, Z. Chen, J. Han, L. Jia and L. Wang: Sirt1 is essential for resveratrol enhancement of hypoxia-induced autophagy in the type 2 diabetic nephropathy rat. *Pathol Res Pract* (2016)
DOI: 10.1016/j.prp.2016.02.001
324. Z. Liu, V. Stanojevic, L. J. Brindamour and J. F. Habener: GLP1-derived nonapeptide GLP1(28-36)amide protects pancreatic beta-cells from glucolipotoxicity. *J Endocrinol*, 213(2), 143-54 (2012)
- DOI: 10.1530/joe-11-0328
325. C. He, M. C. Bassik, V. Moresi, K. Sun, Y. Wei, Z. Zou, Z. An, J. Loh, J. Fisher, Q. Sun, S. Korsmeyer, M. Packer, H. I. May, J. A. Hill, H. W. Virgin, C. Gilpin, G. Xiao, R. Bassel-Duby, P. E. Scherer and B. Levine: Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. *Nature*, 481(7382), 511-5 (2012)
DOI: 10.1038/nature10758
326. C. L. Chung, I. Lawrence, M. Hoffman, D. Elgindi, K. Nadhan, M. Potnis, A. Jin, C. Sershon, R. Binnebose, A. Lorenzini and C. Sell: Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. *Geroscience*, 41, 6 (2019)
DOI: 10.1007/s11357-019-00113-y
327. G. Xu, H. Shen, E. Nibona, K. Wu, X. Ke, M. A. Al Hafiz, X. Liang, X. Zhong, Q. Zhou, C. Qi and H. Zhao: Fundc1 is necessary for proper body axis formation during embryogenesis in zebrafish. *Sci Rep*, 9(1), 18910 (2019)
DOI: 10.1038/s41598-019-55415-0
328. N. Mu, Y. Lei, Y. Wang, Y. Wang, Q. Duan, G. Ma, X. Liu and L. Su: Inhibition of SIRT1/2 upregulates HSPA5 acetylation and induces pro-survival autophagy via ATF4-DDIT4-mTORC1 axis in human lung cancer cells. *Apoptosis* (2019)
DOI: 10.1007/s10495-019-01559-3
329. L. Zhou, W. Gao, K. Wang, Z. Huang, L. Zhang, Z. Zhang, J. Zhou, E. C. Nice and C. Huang: Brefeldin A inhibits colorectal cancer growth by triggering Bip/Akt-regulated autophagy. *Faseb j*, fj201801983R (2019)

DOI: 10.1096/fj.201801983R

330. K. Maiese, Y. C. Shang, Z. Z. Chong and J. Hou: Diabetes mellitus: channeling care through cellular discovery. *Curr Neurovasc Res*, 7(1), 59-64 (2010)
DOI: BSP/CNR/E-Pub/00008

Abbreviations: AD: Alzheimer's disease, AMPK: AMP activated protein kinase, Atg: Autophagic related genes, Deptor: DEP domain-containing mTOR interacting protein, DM: Diabetes mellitus, EPO: Erythropoietin, 4EBP1: Eukaryotic initiation factor 4E (eIF4E: - binding protein 1, ERKs: Extracellular signal-regulated kinases, TSC1/TSC2: Hamartin (tuberous sclerosis 1: /tuberin (tuberous sclerosis 2: , IRS-1: Insulin receptor substrate 1, mLST8: Mammalian lethal with Sec13 protein 8, termed mLST8, mTOR: Mechanistic target of rapamycin, mTORC1: mTOR Complex 1, mTORC2: mTOR Complex 2, NCDs: Non-communicable diseases, p70S6K: p70 ribosomal S6 kinase, PARP: poly (ADP-ribose) polymerase (PARP), PS: Phosphatidylserine, PDK1: Phosphoinositide-dependent kinase 1, PRAS40: Proline rich Akt substrate 40 kDa, Akt: Protein kinase B, SIRT1: Silent mating type information regulation 2 homolog 1 (*Saccharomyces cerevisiae*), US: United States, USD: United States dollars

Key Words: Alzheimer's disease, AMPK, Apoptosis, Autophagy, Dementia, Diabetes Mellitus, Erythropoietin, Nicotinamide, mTOR, Oxidative Stress, PARP, Rapamycin, Sirtuin, SIRT1, Review

Send correspondence to: Kenneth Maiese, Cellular and Molecular Signaling, New York, New York 10022, E-mail: wntin75@yahoo.com